

Publikationen aus der Klinik für Hämatologie, Onkologie und Palliativmedizin seit 2004

I. Originalarbeiten

1. **Maschmeyer G**, Böhme, A, Buchheidt D, Cornely OA, Fricke HJ, Karthaus M, Lehrnbecher T, Link, Shah PM, Wilhelm M. Diagnostik und Therapie von Infektionen bei Patienten in der Hämatologie und Onkologie. Leitlinien der Sektion Infektionen in der Hämatologie/Onkologie der Paul-Ehrlich-Gesellschaft e.V. *Chemother J* 2004;13:134-41.
2. Zaspel U, Denning DW, Lemke AJ, Greene R, Schürmann D, **Maschmeyer G**, Ruhnke M, Herbrecht R, Ribaud P, Lortholary O, Zonderland H, Rabe KF, Röttgen R, Bittner R, Neumann K, Oestmann JW. Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist. *Eur Radiol* 2004;14:2030-7.
3. Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, **Pasold R**, Döhner K, Ganser A, Döhner H, Heil G. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. *J Clin Oncol* 2004;22:3741-50.
4. Koenigsmann M, Knauf W, Herold M, **Pasold R**, Müller G, Eschenburg H, Kahl C, Lakner V, Assmann M, Jentsch-Ullrich K, Mohren M, Bartsch R, Franke A. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma—a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO). *Leuk Lymphoma* 2004;45:1821-7.
5. Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, **Rothmann F**, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood* 2004;104:3064-71.
6. Reich G, Cornely OA, Sandherr M, Kubin T, Krause S, Einsele H, Thiel E, Bellaire T, Dörken B, **Maschmeyer G**. Empirical antimicrobial monotherapy in patients after high dose chemotherapy and autologous stem cell transplantation. A randomized, multicentre trial. *Br J Haematol* 2005;130:265-70.
7. Westermann J, **Maschmeyer G**, Lessen A, Dörken B, Pezzutto A (2005): CD52 is not a promising immunotherapy target for most patients with multiple myeloma. *Int J Hematol* 2005;82:248-50.
8. Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, **Rothmann F**, Lübbert M, Ganser A, Aivado M, Heinsch M, Aul C. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherolalpha: a phase II study. *Ann Hematol* 2005;84:389-94.
9. Korfel A, Martus P, Nowrousian MR, Hossfeld DK, Kirchen H, Brücher J, Stelljes M, Birkmann J, Peschel C, **Pasold R**, Fischer L, Jahnke K, Thiel E; German primary central nervous system lymphoma Study Group (G-PCNSL-SG). Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. *Br J Haematol* 2005;128:177-83.
10. Betts R, Glasmacher A, Maertens J, **Maschmeyer G**, Vazquez J, Teppler H, Taylor A, Lupinacci R, Sable C, Kartsonis N. Efficacy of caspofungin against invasive *Candida* or invasive *Aspergillus* infections in neutropenic patients. *Cancer* 2006;106:466-73.

11. **Haas A, Maschmeyer G.** Das ökonomische Dilemma. Personenbezogene Dienstleistungen unter den DRG-Bedingungen am Beispiel der Betreuung krebskranker Patienten. *Krankenhaus Umschau* 05-2006;4:12-6.
12. Schiel X, Link H, **Maschmeyer G**, Glaß B, Cornely OA, Buchheidt D, Wilhelm M, Silling G, Helmerking M, Hiddemann W, Ostermann H, Hentrich M for the Study Group of the Paul Ehrlich-Societ. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. *Infection* 2006;34:118-26.
13. **Maschmeyer G, Haas A.** Defining clinical failure for salvage studies. *Med Mycol* 2006;44:S315-8.
14. **Maschmeyer G, Haas A.** Infektiöse Komplikationen als Folge der Behandlung mit Nukleosidanaloga und monoklonalen Antikörpern. *Dtsch Med Wschr* 2006;131:2414-9 und *TumorDiagnTher* 2006;27:266-72.
15. **Haas A, Kahle W, Maschmeyer G.** Personalbedarfsanalyse für den ärztlichen Dienst unter target costing Bedingungen. *Krankenhaus Umschau* 11/2006;11:1064-7.
16. Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachzelt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, **Pasold R**, Friedrich T, Helbig W, Niederwieser D; East German Study Group of Hematology and Oncology (OSHO). Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). *J Cancer Res Clin Oncol.* 2006;132:205-12.
17. Glasmacher A, Cornely O, Ullmann AJ, Wedding U, Bodenstein H, Wandt H, Boewer C, **Pasold R**, Wolf HH, Hänel M, Dölken G, Junghanss C, Andreesen R, Bertz H; Itraconazole Research Group of Germany. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. *J Antimicrob Chemother* 2006;57:317-25.
18. Eichhorst BF, Busch R, Hopfinger G, **Pasold R**, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M; German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. *Blood* 2006;107:885-91.
19. Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachzelt K, Boewer C, Schirmer V, Weniger J, **Pasold R**, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Müller C, Müller C; for the East German Study Group Hematology and Oncology (OSHO). Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). *J Cancer Res Clin Oncol.* 2006;132:105-12.
20. **Haas A, Maschmeyer G.** Die elektronische Gesundheitskarte in Deutschland. *Brandenburgisches Ärzteblatt* 2006;11-2006:291-3.
21. **Haas A, Lobeck H, Hummel M, Maschmeyer G.** Anhaltende Remission nach Immuntherapie bei zuvor refraktärem peripheren T-Non-Hodgkin-Lymphom. *Dtsch Med Wschr* 2006;131:2386-9.

22. Montemurro M, Kiefer T, Schüler F, Al-Ali HK, Wolf HH, Herbst R, **Haas A**, Helke K, Theilig A, Lotze C, Hirt C, Niederwieser D, Schwenke M, Krüger WH, Dölken G. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted wholebrain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. *Ann Oncol* 2007;18:665-71.
23. Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berde WE, Weissinger F, Schleicher J, Egerer G, **Haas A**, Schirren R, Beyer J, Bokemeyer C, Rick O; German Testicular Cancer Study Group. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. *J Clin Oncol* 2007;25:2778-84.
24. Herold M, **Haas A**, Srock S, Nesper S, Al-Ali KH, Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grünhagen U; East German Study Group, Hematology and Oncology Study. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. *J Clin Oncol* 2007;25:1986-92.
25. **Maschmeyer G, Haas A**, Dickerhoff R, Kleber FX. Pulmonale Hypertonie bei Sichelzellerkrankheiten. *Epidemiologie, Pathogenese, Diagnostik, Therapie. Dtsch Med Wschr* 2007;132:103-7.
26. De Pauw B, Walsh TJ, Donnelly JP, Stevens D, Edwards JE, Calandra T, Pappas P, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, **Maschmeyer G**, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel J, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. Revised definitions of the EORTC/MSG consensus group for invasive fungal diseases. *Clin Infect Dis* 2008;46:1813-21.
27. **Rothmann F, Maschmeyer G**. Systemische AL-Amyloidose: neue Daten zur Therapie mit Thalidomid, Cyclophosphamid, Dexamethason und Lenalidomid. *Arzneimittelbrief* 2008;41:60-1.
28. Cornely OA, Böhme A, Reichert D, Reuter S, **Maschmeyer G**, Maertens J, Buchheidt D, Paluszewska M, Arenz D, Bethé U, Effelsberg J, Lövenich H, Sieniawski M, **Haas A**, Einsele H, Eimermacher H, Martino R, Silling G, Hahn M, Wacker S, Ullmann AJ, Karthaus M. Secondary prophylaxis after invasive pulmonary fungal infections in acute myelogenous leukemia patients from 25 European cancer centers. *J Antimicrob Chemother* 2008;61:939-46.
29. Pönisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U, Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, **Haas A**, Kreibich U, Niederwieser D; East German Study Group of Haematology and Oncology (OSHO). Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. *Br J Haematol* 2008;143:191-200.
30. Kiefer T, Krüger WH, Montemurro M, Schüler F, Hirt C, **Pasold R**, Niederwieser D, Schwenke M, Dölken G. Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma. *Transfusion* 2008;48:2624-8.
31. Hirt C, Schüler F, Kiefer T, Schwenke C, **Haas A**, Niederwieser D, Nesper S, Assmann M, Srock S, Rohrberg R, Dachsel K, Leithäuser M, Rabkin CS, Herold M, Dölken G. Rapid

and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. *Br J Haematol* 2008;141:631-40.

32. Wolf HH, Leithäuser M, **Maschmeyer G**, Salwender H, Klein U, Chaberny I, Weissinger F, Buchheidt D, Ruhnke M, Egerer G, Fätkenheuer G, Mousset S. Central venous catheter-related infections in hematology and oncology: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 2008;87:863-76.
33. **Maschmeyer G**, Neuburger S, **Fritz L**, Böhme A, Penack O, Schwerdtfeger R, Buchheidt D, Ludwig WD. A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. *Ann Oncol* 2009;20:1560-4.
34. **Maschmeyer G**, Beinert T, Buchheidt D, Cornely OA, Einsele H, Heinz W, Heussel CP, Kahl C, Kiehl M, Lorenz J, Hof H, Mattiuzzi G. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients. 2008 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Oncology. *Eur J Cancer* 2009;45:2462-72.
35. Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, Ludwig WD, Staib P, Aul C, Grüneisen A, Kern W, Reichle A, Serve H, Berdel WE, Braess J, Spiekermann K, Wörmann B, Sauerland MC, Heinecke A, Hiddemann W, Hehlmann R, Büchner T; **German AML Cooperative Group**. High-dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. *Leukemia* 2009;23: 2248-58.
36. Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz W, Karthaus M, Krause SW, Krüger W, **Maschmeyer G**, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ. Primary prophylaxis of invasive fungal infections in patients with hematological malignancies. Recommendations of the Infectious Diseases Working Party of the German Society of Hematology and Oncology. *Haematologica* 2009;94:113-22.
37. Böhme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, Enzensberger R, Hebart H, Heinz W, Junghanss C, Karthaus M, Krüger W, Krug U, Kubin T, Penack O, Reichert D, Reuter S, Silling G, Südhoff T, Ullmann AJ, **Maschmeyer G**. Treatment of invasive fungal infections in cancer patients – Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 2009;88:97-110.
38. Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, **Maschmeyer G**, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. *J Clin Oncol* 2009;27:61-9.
39. Vehreschild JJ, Sieniawski M, Reuter S, Arenz D, Reichert D, Maertens J, Böhme A, Martino R, **Maschmeyer G**, Rüping MJGT, Ullmann AJ, Cornely OA. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: an analysis of data from a multinational case registry. *Int J Antimicrob Agents* 2009;34:446-50.
40. Basara N, Schulze A, Wedding U, Mohren M, **Gerhardt A**, Junghanss C, Peter N, Dölken G, Becker C, Heyn S, Kliem C, Lange T, Krahl R, Pönisch W, Fricke HJ, Sayer HG, Al-Ali H, Kamprad F, Niederwieser D; East German Study Group Hematology and Oncology (OSHO). Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in

high-risk acute myeloid leukaemia patients in first complete remission. *Leukemia* 2009;23:635-40.

41. Tintelnot K, Just-Nübling G, Horré R, Graf B, Sobottka I, Seibold M, **Haas A**, Kaben U, De Hoog GS. A review of German *Scedosporium prolificans* cases from 1993 to 2007. *Med Mycol* 2009;47:351-8.
42. Rüping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C, Beisel C, Herbrecht R, Roth Y, Silling G, Ullmann AJ, Borchert K, Egerer G, Maertens J, **Maschmeyer G**, Simon A, Wattad M, Fischer G, Vehreschild JJ, Cornely OA. Forty-one recent cases of invasive zygomycosis from a global clinical registry. *J Antimicrob Chemother* 2010;65:296-302.
43. Krug U, Rölling C, Koschmieder A, Heincke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C, **German Acute Myeloid Leukemia Cooperative Group** and Study Alliance Leukemia Investigators. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. *Lancet* 2010;376:2000-8.
44. Thuss-Patience PC, Kretzschmar A, Dogan Y, **Rothmann F**, Blau I, Schwaner I, Breithaupt K, Bichev D, Grothoff M, Grieser C, Reichardt P. Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. *Br J Cancer* 2011;105:505-12.
45. Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhöfer N, Rohrberg R, Söling U, Burkhard O, Westermann A, Goede V, Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Döhner H, Emmerich B, Hallek M; **German CLL Study Group** (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. *Blood* 2009;114:3382-91.
46. Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; **German CLL Study Group** (GCLLSG). Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis *Blood* 2011;117:1817-21.
47. Al-Ali H, Jaekel N, Junghans C, **Maschmeyer G**, Krahl R, Cross M, Hoppe G, Niederwieser D. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. *Leuk Lymphoma* 2012;53:110-7.
48. Ruhnke M, Böhme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, Enzensberger R, Hebart H, Heussel CP, Horgner M, Hof H, Karthaus M, Krüger W, **Maschmeyer G**, Penack O, Ritter J, Schwartz S. Diagnosis of invasive fungal infections in haematology and oncology - Guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). *Ann Oncol* 2012;23:823-33.
49. Vehreschild MLGT, Meissner A, Cornely OA, **Maschmeyer G**, Neumann S, von Lilienfeld-Toal M, Karthaus M, Wattad M, Staib P, Hellmich M, Christ H, Vehreschild JJ. Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. *Haematologica* 2011;96:1855-60.
50. Kiefer T, Hirt C, Späth C, Schüler F, Al-Ali HK, Wolf HH, Herbst R, **Maschmeyer G**, Helke K, Kessler C, Niederwieser D, Busemann C, Schroeder H, Vogelgesang S, Kirsch M, Montemurro M, Kröger WH, Dölken G. Long-term follow-up of high-dose

chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study. *Ann Oncol* 2012;23:1809-12.

51. Reinwald M, Spiess B, Heinz W, Vehreschild J, Lass-Floerl C, Kiehl M, Schultheis B, Krause S, Wolff H, Bertz H, **Maschmeyer G**, Hofmann W, Buchheidt D. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: A multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. *Eur J Haematol* 2012;89:120-7.
52. Gökbüget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, Fietkau R, Freund M, Ganser A, Ludwig WD, **Maschmeyer G**, Rieder R, Schwartz S, Serve H, Thiel E, Brüggemann M, Hoelzer D. Adults with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for SCT and targeted therapies. *Blood* 2012;120:1868-76.
53. Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S; **German CLL Study Group**. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. *Blood* 2012;119:4851-9.
54. Dufour A, Schneider F, Hoster E, Benthous T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; **AML CG Study Group**. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. *Ann Hematol* 2012;91:1051-63.
55. Oertel K, Spiegel K, Schmalenberg H, Dietz A, **Maschmeyer G**, Kuhnt T, Südhoff H, Wendt TG, Guntinas-Lichius O. Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). *BMC Cancer* 2012;12:483.
56. **Maschmeyer G**, Heinz WJ, Hertenstein B, Horst HA, Requadt C, Wagner T, Cornely OA, Löffler J, Ruhnke M on behalf of the IDEA study investigators. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: A randomised, double-blind, placebo-controlled, multicentre study. *Eur J Clin Microbiol Infect Dis* 2013;32:679-89.
57. Rummel MJ, Niederle N, **Maschmeyer G**, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balsler C, Kaiser U, Weidmann E, Dürk H, Ballo H, Strauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment in patients with indolent and mantle cell lymphomas: results of a prospective, open-label, multi-centre, randomised, phase 3, non-inferiority trial. *Lancet* 2013;381:1203-10.
58. Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; **German High-Grade Lymphoma Study Group (DSHNHL)**. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). *Lancet Oncol* 2012;13:1250-9.
59. Vehreschild MJ, Vehreschild JJ, Hübel K, Hentrich M, Schmidt-Hieber M, Christopeit M, **Maschmeyer G**, Schalk E, Cornely OA, Neumann S. Diagnosis and management of

gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Oncol* 2013;24:1189-202.

60. Neumann S, Krause SW, **Maschmeyer G**, Schiel X, von Lilienfeld-Toal M. Primary prophylaxis of bacterial infections and *Pneumocystis jirovecii* pneumonia in patients with hematological malignancies and solid tumors. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 2013; 92:433-42.
61. Wongso D, Fuchs M, Pluetschow A, Klimm B, Sasse S, Hertenstein B, **Maschmeyer G**, Vieler T, Dührsen U, Lindemann W, Aulitzky W, Diehl V, Borchmann P, Engert A. Treatment-related mortality in patients with advanced-stage Hodgkin Lymphoma: an analysis of the German Hodgkin Study Group (GHSg). *J Clin Oncol* 2013;31:2819-24.
62. Cross M, Bach E, Tran T, Krahl R, Jaekel N, Niederwieser D, Junghanß C, **Maschmeyer G**, Al-Ali HK. Pre-treatment LINE-1 methylation levels, not early hypomethylation under treatment, predict haematological response to azacitidine in elderly patients with acute myeloid leukaemia. *OncoTargetsTher* 2013;6:741-8.
63. Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G, Krüger W, Link H, Neumann S, Ostermann H, Panse J, Penack O, Rieger C, Schmidt-Hieber M, Silling G, Südhoff T, Ullmann AJ, Wolf HH, **Maschmeyer G**, Böhme A. Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 2014;93:13-32.
64. Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt D, Ruhnke M, Penack O, Salwender H, Wolf HH, Christopeit M, Neumann S, **Maschmeyer G**, Karthaus M. Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. *Ann Oncol* 2014;25:936-947.
65. Vehreschild JJ, Böhme A, Cornely OA, Kahl C, Karthaus M, Kreuzer KA, **Maschmeyer G**, Mousset S, Ossendorf V, Penack O, Vehreschild MJGT, Bohlius J. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy – Evidence-based guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). *Ann Oncol* 2014;25:1709-18.
66. **Maschmeyer G**, Carralatà J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M, Salwender H, Schmidt-Hieber M, Azoualy E. Diagnosis and Antimicrobial Therapy of Lung Infiltrates in Febrile Neutropenic Patients (allogeneic SCT excluded) - Updated Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Oncol* 2014;26: 21-33.
67. Krüger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, Grobe N, **Maschmeyer G**, Niederwieser D, Dölken G. Allogeneic stem cell transplantation for mantle cell lymphoma - Final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). *Ann Hematol* 2014;93:1587-97.
68. **Maschmeyer G**, Patterson TF. Our 2014 approach to breakthrough invasive fungal infection. *Mycoses* 2014;57:645-51.
69. Tacke D, Buchheidt D, Karthaus M, Krause SW, **Maschmeyer G**, Neumann S, Ostermann H, Penack O, Rieger C, Ruhnke M, Sandherr M, Schweer KE, Ullmann AJ, Cornely OA. Primary prophylaxis of invasive fungal infections in patients with

haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. *Ann Hematol* 2014;93:1449-56.

70. Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, Roilides E, Styczynski J, Warris A, Lehrnbecher T; Fourth European Conference on Infections in Leukaemia; Infectious Diseases Working Party of the European Group for Blood Marrow Transplantation (EBMT-IDWP); Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC-IDG); **International Immunocompromised Host Society (ICHS)**; European Leukaemia Net (ELN). Collaborators: Akan H, Akova M, Averbuch D, Barnes RM, Blijlevens N, Calandra T, Cordonnier C, Cornely O, Donnelly P, Drgona L, Einsele H, Gachot B, Girmenia C, Gyssens I, Heinz W, Herbrecht R, Hirsch H, Hubacek P, Kibbler C, Klyasova G, Kouba M, Lagrou C, Maertens J, Marchetti O, Martino R, **Maschmeyer G**, Masszi T, Matthes-Martin S, Micozzi A, Mohty B, Munoz P, Nadal D, Orasch C, Racil Z, Ribaud P, Sinko J, Tanase A, Tumbarello M, Verweij P, Viscoli C. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. *Lancet Oncol* 2014;15: e327-40.
71. **Maschmeyer G**, Mügge LO, Kämpfe D, Kreibich U, Wilhelm S, Aßmann M, Schwarz M, Kahl C, Köhler S, Grobe N, Niederwieser D: A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012. *J Cancer Res Clin Oncol* 2015;141:1639-44.
72. Thiel A, Schetelig J, Pönisch W, Schäfer-Eckart K, Aulitzky W, Peter N, Schulze A, **Maschmeyer G**, Neugebauer S, Herbst R, Hänel A, Morgner A, Kroschinsky F, Bornhäuser M, Lange T, Wilhelm M, Niederwieser D, Ehninger G, Fiedler F, Hänel M. Mito-FLAG with ara-C as bolus versus continuous infusion in recurrent or refractory AML – Long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). *Ann Oncol* 2015;26:1434-40.
73. Herold M, Scholz CW, **Rothmann F**, Hirt C, Lakner V, Naumann R. Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma. *J Cancer Res Clin Oncol* 2015;141:1689-95.
74. Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, **Maschmeyer G**, Kofahl-Krause D, Niederle N, Heil G, Losem C, Welslau M, Brugger W, Germing U, Kronenwett R, Barth J, Rummel MJ, Haas R, Kobbe G. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immuno-chemotherapy. *Blood* 2015;126:1407-14.
75. Kahl C, Krahl R, Becker C, Al-Ali HK, Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, **Maschmeyer G**, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf H-H, Niederwieser D. Long term follow-up of the AML97-study for patients 60 years and above with acute myeloid leukemia: A study of the East German Hematology and Oncology Study Group (OSHO). *J Cancer Res Clin Oncol* 2016;142:305-15.
76. Rummel M, Kaiser U, Balsler C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas (Hahn M, Mueller S, Klausmann M, Krüger S, Aulmann C, Borghardt J, Korfel A, Goerner M, Just M, Schäfer E, von Grünhagen U, Bernhard H, Kojouharoff G, Schroeder J, Selbach J, Schütte HJ, Knauf W, Jäger E, Bergmann L, Wilke I, Schliesser G, Kaebisch A, Blau W, Burchardt A, Rummel M, Depenbusch R, Rohrberg R, Neef U, Müller-Hagen S, Dürk H, Lautenschläger G, Burk M, Mao R, Kofahl-Krause D, Ganser A, Hahn L,

Kaiser U, Link H, Mahlmann S, Prümmer O, Neise M, Stauch M, Müller L, Niederle N, Heider A, Neuhaus T, Heil G, Hünermund K, Balsler C, Weidenbach F, Eggert J, Abenhardt W, Bojko P, Hitz H, Losem C, Plewe D, Hutzschenreuter U, Zimber J, Balló HE, Boeck HP, **Maschmeyer G, Rothmann F**, Krammer-Steiner B, Baldus M, Matzdorff A, Fiechtner H, Brugger W, Sandherr M, Perker M, Josten KM, Schellenberger U, Schlag R. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. *Lancet Oncol* 2016;17: 57-66.

77. Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, **Maschmeyer G**, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T, for the German Acute Myeloid Leukemia Cooperative Group (AMLCG). Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. *Leukemia* 2016;30:1230-6.
78. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, Duyvené de Wit T, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ, André M, Andre-Schmutz I, Bacigalupo A, Bochud PY, den Boer M, Bonini C, Camaschella C, Cant A, Cappellini MD, Lo Celso C, Dimopoulos M, Douay L, Dzierzak E, Einsele H, Ferreri A, Cazzola M, De Franceschi L, Gaulard P, Gottgens B, Greinacher A, Gresele P, Gribben J, de Haan G, Hansen JB, Hochhaus A, Kadir R, Kaveri S, Kouskoff V, Kühne T, Kyrle P, Ljungman P, **Maschmeyer G**, Méndez-Ferrer S, Milsom M, Mummery C, Ossenkoppele G, Pecci A, Peyvandi F, Philipson S, Reitsma P, Ribera JM, Risitano A, Rivella S, Ruf W, Schroeder T, Scully M, Socie G, Staal F, Stanworth S, Stauder R, Stilgenbauer S, Tamary H, Theilgaard-Mönch K, Thein SL, Tilly H, Trnety M, Vainchenker W, Vannucchi AM, Viscoli C, Vrielink H, Zaaier H, Zanella A, Zolla L, Zwaginga JJ, Aguilar Martinez P, van den Akker E, Allard S, Anagnou N, Andolfo I, Andrau JC, Angelucci E, Anstee D, Aurer I, Avet-Loiseau H, Aydinok Y, Bakchoul T, Balduini A, Barcellini W, Baruch D, Baruchel A, Bayry J, Bento C, van den Berg A, Bernardi R, Bianchi P, Bigas A, Biondi A, Bohonek M, Bonnet D, Borchmann P, Borregaard N, Brækkan S, van den Brink M, Brodin E, Bullinger L, Buske C, Butzeck B, Cammenga J, Campo E, Carbone A, Cervantes F, Cesaro S, Charbord P, Claas F, Cohen H, Conard J, Coppo P, Vives Corrons JL, da Costa L, Davi F, Delwel R, Dianzani I, Domanović D, Donnelly P, Dovč Drnovsek T, Dreyling M, Du MQ, Dufour C, Durand C, Efremov D, Eleftheriou A, Elion J, Emonts M, Engelhardt M, Ezine S, Falkenburg F, Favier R, Federico M, Fenaux P, Fitzgibbon J, Flygare J, Foà R, Forrester L, Galacteros F, Garagiola I, Gardiner C, Garaud O, van Geet C, Geiger H, Geissler J, Germing U, Ghevaert C, Girelli D, Godeau B, Gökbüget N, Goldschmidt H, Goodeve A, Graf T, Graziadei G, Griesshammer M, Gruel Y, Guilhot F, von Gunten S, Gyssens I, Halter J, Harrison C, Hartevelde C, Hellström-Lindberg E, Hermine O, Higgs D, Hillmen P, Hirsch H, Hoskin P, Huls G, Inati A, Johnson P, Kattamis A, Kiefel V, Kleanthous M, Klump H, Krause D, Kremer Hovinga J, Lacaud G, Lacroix-Desmazes S, Landman-Parker J, LeGouill S, Lenz G, von Lilienfeld-Toal M, von Lindern M, Lopez-Guillermo A, Lopriore E, Lozano M, MacIntyre E, Makris M, Mannhalter C, Martens J, Mathas S, Medvinsky A, Menendez P, Migliaccio AR, Miharada K, Mikulska M, Minard V, Montalbán C, de Montalambert M, Montserrat E, Morange PE, Mountford J, Muckenthaler M, Müller-Tidow C, Mumford A, Nadel B, Navarro JT, El Nemer W, Noizat-Pirenne F, O'Mahony B, Oldenburg J, Olsson M, Oostendorp R, Palumbo A, Passamonti F, Patient R, Peffault de Latour R, Pflumio F, Pierelli L, Piga A, Pollard D, Raaijmakers M, Radford J, Rambach R, Koneti Rao A, Raslova H, Rebullà P, Rees D, Ribrag V, Rijneveld A, Rinalducci S, Robak T, Roberts I, Rodrigues C, Rosendaal F, Rosenwald A, Rule S, Russo R, Saglio G, Sanchez M, Scharf RE, Schlenke P, Semple J, Sierra J, So-Osman C, Soria JM, Stamatopoulos K, Stagmayr B, Stunnenberg H, Swinkels D, Tabor Barata JP, Taghon T, Taher A, Terpos E, Thachil J, Tissot JD, Touw I, Toye A, Trappe R, Traverse-Glehen A, Unal S, Vaulont S, Viprakasit V, Vitolo U, van Wijck R, Wójtowicz A, Zeerleder S, Zieger B. The European Hematology Association Roadmap for European Hematology Research. A Consensus Document. *Haematologica* 2016;101:104-114.

79. **Maschmeyer G**, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P on behalf of the European Conference on Infections in Leukemia (ECIL), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). ECIL guidelines for treatment of *Pneumocystis jirovecii* pneumonia (PcP) in non HIV-infected haematology patients. *J Antimicrob Chemother* 2016;71:2405-13.
80. Alanio A, Hauser PM, Lagrou K, Melchers WJG, Helweg-Larsen J, Matos O, Cesaro S, **Maschmeyer G**, Einsele H, Donnelly JP, Cordonnier C, Maertens J, Bretagne S on behalf of the 5th European Conference on Infections in Leukemia (ECIL5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS), and the European Leukaemia Network (ELN). ECIL guidelines for the diagnosis of *Pneumocystis jirovecii* pneumonia in patients with hematological malignancies and stem cell transplant recipients. *J Antimicrob Chemother* 2016;71:2386-96.
81. Cordonnier C, Cesaro S, **Maschmeyer G**, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJG, Helweg-Larsen J, Matos O, Bretagne S, Maertens J on behalf of the European Conference on Infections in Leukemia (ECIL), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS), and the European Leukaemia Network (ELN). *Pneumocystis jirovecii* pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. *J Antimicrob Chemother* 2016;71:2379-85.
82. Maertens J, Cesaro S, **Maschmeyer G**, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJG, Helweg-Larsen J, Matos O, Bretagne S, Cordonnier C on behalf of the 5th European Conference on Infections in Leukemia (ECIL5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS), and the European Leukaemia Network (ELN). ECIL guidelines for preventing *Pneumocystis jirovecii* pneumonia in patients with haematological malignancies and stem cell transplant recipients. *J Antimicrob Chemother* 2016;71:2397-404.
83. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, **Maschmeyer G**, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. *Lancet* 2016;388:565-75.
84. Schmidt-Hieber M, Silling G, Schalk E, Heinz W, Panse J, Penack O, Christopeit M, Buchheidt D, Meyding-Lamadé U, Hähnel S, Wolf HH, Ruhnke M, Schwartz S, **Maschmeyer G**. CNS infections in patients with hematological disorders (including allogeneic stem cell transplantation) – Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Oncol* 2016;27:1207-25.
85. Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V; FIRE-3 Study Group (Aghdassi A, Aulmann C, Bair W, Behringer D, Bohle W, Burkhard O, Breunig E, Constantin C, Demandt M, Denzlinger C, Dürk HA,

- Eggers E, Engel E, Ettrich T, Fauth F, Feder G, Fleck U, Gassmann W, Gehbauer G, Geißler M, Graf D, Haberl C, Hagen V, Harich HD, Hebart H, Herrmann T, Hitz H, Höffkes HG, Hoffmann J, Hoffmann T, Jäger E, Kappauf H, Ketzler S, Kiehl M, Killing B, Koch B, Koch O, Koenigsmann M, Kubin TW, Lambertz H, Lindig RU, Link H, Luhn B, **Maschmeyer G**, Matzdorff A, Meiler J, Menzel J, Michl GM, Mittermüller J, Möhler M, Müller M, Niederle N, Peuser B, Perker M, Johannes A, Pfeiffer G, Pihusch R, Porschen R, Prügl L, Puchtler G, Quietzsch D, Raßmann I, Reeb M, Repp R, Respondek M, Knorrenschild JR, Römmele U, Rost A, Rummel M, Schäfer B, Schanz S, Schepp W, Schlag R, Schleicher J, Schmidt B, Schmidt WE, Schmits R, Schneider-Kappus W, Maria E, Schnoy A, Schulz-Abelius A, Schulze M, Schwella N, Schwittay M, Siebler J, Sieveke JT, Simon H, Slawik HR, Söling U, Spes J, Stötzer O, Truckenbrodt J, Uhlig J, Walther M, Weber E, Weiß J, Wolff T, Zimmer J, Andel J, Dittrich C, Ludwig H, Samonigg H, Scheithauer W, Thaler J, Weltermann A). CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). *Ann Oncol* 2016;27:1565-72.
86. Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W, Mousset S, Neuburger S, Neumann S, Penack O, Silling G, Vehreschild JJ, Einsele H, **Maschmeyer G**; Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation). Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. *Ann Hematol* 2016;95:1435-55.
87. Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, **Maschmeyer G**, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP(escalated) alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. *Lancet Oncol* 2017;18:454-63.
88. Klastersky J, de Naurois J, Rolston K, Rapoport B, **Maschmeyer G**, Apro M, Herrstedt J; ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2016;27(suppl 5):v111-8.
89. Gudiol C, Royo-Cebrecos C, Tebe C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, Cano A, Cervera C, Clemente WT, Martín-Dávila P, Freifeld A, Gómez L, Gottlieb T, Gurguí M, Herrera F, Manzur A, **Maschmeyer G**, Meije Y, Montejo M, Peghin M, Rodríguez-Baño J, Ruiz-Camps I, Sukiennik TC, Carratalà J; BICAR study group. Clinical efficacy of β -lactam/ β -lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β -lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). *BMJ Open* 2017;7:e013268.
90. Cordonnier C, Alanio A, Cesaro S, **Maschmeyer G**, Einsele H, Donnelly JP, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Bretagne S, Maertens J; Fifth European Conference on Infections in Leukemia (ECIL-5; a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response. *J Antimicrob Chemother* 2017;72:1266-8.
91. Inhestern J, Schmalenberg H, Dietz A, Rotter N, **Maschmeyer G**, Jungehülsing M, Grosse-Thie C, Kuhnt T, Görner M, Südhoff H, Wittekindt C, Guntinas-Lichius O. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by

- curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). *Ann Oncol* 2017;28: 1917-1922
92. Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, **Maschmeyer G**, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. *J Clin Oncol* 2017;35:3330-7.
 93. **Maschmeyer G**, Brink I, Jähne D, Arnold R, Schega O. Residual thymic tissue and lymph node involvement by acute myeloid leukaemia presenting as mediastinal, strongly ¹⁸F-DG-PET-positive masses. *Eur J Haematol* 2017;99:286-8.
 94. Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S, Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild JJ, Weissinger F, **Maschmeyer G**. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Hematol* 2017;96:1775-92.
 95. Einsele H, Tapprich C, Baurecht W, Liebisch P, Langer C, Kropff M, Kröger N, Mügge LO, Engelhardt M, Jung W, Wolf HH, Metzner B, Ostermann H, Hart C, Gramatzki M, Kaufmann M, Hertenstein B, Pfreundschuh M, Rösler W, Schmitz N, Fischer T, Heidemann E, **Maschmeyer G**, Kahl C, Dechow T, Kanz L, Brugger W, Hess G, Jäger E, Kiani A, Sezer O, Bentz M, Dürk H, Salwender H, Hebart H, Peest D, Straka C, Knop S. Phase 2 study of bortezomib, cyclophosphamide plus dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. *Br J Haematol* 2017;179:586-97.
 96. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, **Maschmeyer G**, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma. Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet* 2017;390:2790-802.
 97. Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, Bruzzi P, Viscoli C; European Conference on Infections in Leukemia (ECIL); Aljurf M, Barnes R, Blennow O, Bochud PY, Bouza E, Bretagne S, Brüggemann R, Carratala J, Cesaro S, Cornely O, Dalianis T, De La Camara R, Donnelly P, Drgona L, Duarte R, Einsele H, Engelhard D, Fox C, Girmenia C, Groll A, Heldal D, Larsen JH, Herbrecht R, Hirsch H, Johnson E, Klyasova G, Koskuenvo M, Lagrou K, Lewis RE, Ljungman P, Maertens J, **Maschmeyer G**, Nucci M, Padoin C, Pagano L, Pagliuca A, Racil Z, Ribaud P, Rinaldo C, Puechal VR, Roilides E, Robin C, Rovira M, Rupp M, Sanchez S, Schellongowski P, Sedlacek P, Sinko J, Slavin M, Ferreira IS, Styczynski J, Ward K, Witschi AT. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. *J Infect* 2018;76:20-37.
 98. Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, **Maschmeyer G**, Schalk E, Vehreschild JJ, Vehreschild MJGT; AGIHO Working Group. Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Hematol* 2018;97:31-49.
 99. Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause SW, Lehnert N, von Lilienfeld-Toal M, Löhnert AY, **Maschmeyer G**, Teschner D, Ullmann AJ, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf HH, Cornely OA. Primary prophylaxis of invasive fungal infections in patients with

haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). *Ann Hematol* 2018;97:197-207.

100. **Hemmati PG**, Pfeifer K, Vuong LG, Jehn CF, Terwey TH, le Coutre P, Dörken B, Arnold R. Allogeneic stem cell transplantation for non-de novo AML or advanced myelodysplastic syndromes: influence of GvHD and donor lymphocyte infusions on long-term outcome. *Bone Marrow Transplant* 2018;53:101-3.
101. Rieger CT, Liss B, Mellinshoff S, Buchheidt D, Cornely OA, Egerer G, Heinz W, Hentrich M, **Maschmeyer G**, Mayer K, Sandherr M, Silling G, Ullmann A, Vehreschild MJGT, von Lilienfeld-Toal M, Wolf HH, Lehnert N. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors – Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). *Ann Oncol* 2018;29:1354-65.
102. Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, **Maschmeyer G**, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A, on behalf of the PETAL trial investigators. Positron-emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase 3 trial. *J Clin Oncol* 2018;36:2024-34.
103. Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Donnelly JP, Cordonnier C; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN) (Agrawal S, Akova M, Alanio A, Aljurf M, Averbukh D, Barnes R, Blennow O, Bochud PY, Bouza E, Bretagne S, Brüggemann R, Calandra T, Carratalà J, Castagnola E, Cesaro S, Cordonnier C, Cornely OA, Dalianis T, De La Camara R, Donnelly JP, Drgona L, Duarte RF, Einsele H, Engelhard D, Ferreira I, Fox C, Girmenia C, Groll A, Hauser P, Heldal D, Helweg-Larsen J, Herbrecht R, Hirsch H, Hubacek P, Johnson EM, Kibbler C, Klyasova G, Koskenvuo M, Kouba M, Kullberg BJ, Lagrou K, Lewis R, Ljungman P, Maertens JA, Mallet V, Marchetti O, Martino R, **Maschmeyer G**, Matos O, Melchers W, Mikulska M, Munoz P, Nucci M, Orasch C, Padoin C, Pagano L, Pagliuca A, Penack O, Petrikos G, Ráčil Z, Ribaud P, Rinaldo CH, Robin C, Roilides E, Rovira M, Schellongowski P, Sedlacek P, Sinko J, Skiada A, Slavin M, Styczynski J, Tissot F, Van Boemmel F, Viscoli C, Von Lilienfeld-Toal M, Ward K. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. *J Antimicrob Chemother* 2018;73:3221-30.
104. Budau L, Wilhelm C, Moll R, Jäckel J, Hirt C, Dölken G, **Maschmeyer G**, Neubauer E, Strauch K, Burchert A, Herold M, Neubauer A. Low number of intrafollicular T-cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: A secondary analysis of a randomized clinical trial. *J Cancer Res Clin Oncol* 2019;145:2149-56.
105. Albasanz-Puig A, Gudiol C, Parody R, Tebe C, Akova M, Araos R, Bote A, Brunel AS, Calik S, Drgona L, García E, **Hemmati P**, Herrera F, Ibrahim KY, Isler B, Kanj S, Kern W, Maestro de la Calle G, Manzur A, Marin JI, Márquez-Gómez I, Martín-Dávila P, Mikulska M, Montejo JM, Montero M, Morales HMP, Morales I, Novo A, Oltolini C, Peghin M, Del Pozo JL, Puerta-Alcalde P, Ruiz-Camps I, Sipahi OR, Tilley R, Yáñez L, Gomes MZR, Carratalà J; IRONIC study group. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with *Pseudomonas aeruginosa* bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. *BMJ Open* 2019;9:e025744.

106. Waldhüter N, Köhler W, **Hemmati PG**, Jehn C, Peceny R, Vuong GL, Arnold R, Kühl JS. Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning for adult cerebral X-linked adrenoleukodystrophy. *J Inher Metab Dis* 2019;42:313-24.
107. Neuendorff NR, **Hemmati P**, Arnold R, Ihlow J, Dörken B, Müller-Tidow C, Westermann J. BCR-ABL(+) acute myeloid leukemia: are we always dealing with a high-risk disease? *Blood Adv* 2018;2:1409-11.
108. Hammer Q, Rückert T, Borst EM, Dunst J, Haubner A, Durek P, Heinrich F, Gasparoni G, Babic M, Tomic A, Pietra G, Nienen M, Blau IW, Hofmann J, Na IK, Prinz I, Koenecke C, **Hemmati P**, Babel N, Arnold R, Walter J, Thurley K, Mashreghi MF, Messerle M, Romagnani C. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. *Nat Immunol* 2018;19:453-63.
109. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, **Hemmati P**, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Bories M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. *Nat Med* 2018;24:282-91.
110. Knop S, Liebisch P, Meisner C, Holler E, Engelhardt M, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Wandt H, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, **Maschmeyer G**, Heidemann E, Svaldi M, Langer Ch, Hebart H, Kanz L, Einsele H, on behalf of Deutsche Studiengruppe Multiples Myelom. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. *Leukemia* 2019;33:2710-9.
111. Salmanton-García J, Seidel D, Koehler P, Mellinghoff SC, Herbrecht R, Klimko N, Ráčil Z, Falces-Romero I, Ingram P, Benítez-Peñuela MÁ, Rodríguez JY, Desoubeaux G, Barac A, García-Vidal C, Hoenigl M, Mehta SR, Cheng MP, Klyasova G, Heinz WJ, Iqbal N, Krause R, Ostermann H, Penack O, Schalk E, Sheppard DC, Willinger B, Wisplinghoff H, Vehreschild JJ, Cornely OA, Vehreschild MJGT; FungiScope® ECMM/ISHAM Working Group (Khedr RA, Arencibia-Núñez A, Avilés-Robles M, Banke I, Basher A, Benachinamardi K, Bertz H, Chakrabarti A, Drgona L, García-Martínez J, García-Rodríguez J, Gräber S, Härter G, Klein M, Kouba M, Lee DG, Le Govic Y, Leo F, Maertens J, **Maschmeyer G**, Meintker L, Mo XD, Müller LK, Müller N, Nel JS, Novák J, Patel A, Pfäfflin F, Pozo-Laderas JC, Puerta-Alcalde P, Rodríguez-Guardado A, Schroers R, Shekar V, Sheno S, Silling G, Vinh D, Waizel-Haiat S, Yee Yee MY, Prakash PY, Žák P). Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). *J Antimicrob Chemother* 2019;74:3315-27.
112. Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, **Maschmeyer G**, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A. PET-guided treatment

in early-stage favourable Hodgkin lymphoma: final results of the international, randomised phase 3 HD16 trial by the German Hodgkin Study Group. *J Clin Oncol* 2019;37:2835-45.

113. Dietz A, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M, Kölbl O, Hautmann MG, Strutz J, Schreiber F, Bockmühl U, Schilling V, Feyer P, de Wit M, **Maschmeyer G**, Jungehülsing M, Schroeder U, Wollenberg B, Sittel C, Münter M, Lenarz T, Klussmann JP, Guntinas-Lichius O, Rudack C, Eich HT, Foerg T, Preyer S, Westhofen M, Welkoborsky HJ, Esser D, Thurnher D, Remmert S, Sudhoff H, Görner M, Bünzel J, Budach V, Held S, Knödler M, Lordick F, Wiegand S, Vogel K, Boehm A, Flentje M, Keilholz U. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. *Ann Oncol* 2018;29:2105-14.
114. Ruhnke M, Behre G, Buchheidt D, Christopheit M, Hamprecht A, Heinz W, Heussel CP, Horger M, Kurzai O, Karthaus M, Löffler J, **Maschmeyer G**, Penack O, Rieger C, Rickerts V, Ritter J, Schmidt-Hieber M, Schuelper N, Schwartz S, Ullmann A, Vehreschild JJ, von Lilienfeld-Toal M, Weber T, Wolf HH. Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). *Mycoses* 2018;61:796-813.
115. Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, **Maschmeyer G**, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nüchel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. *Ann Hematol* 2019;98:897-907.
116. Schmidt-Hieber M, Teschner D, **Maschmeyer G**, Schalk E. Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation. *Expert Rev Anti Infect Ther* 2019;17:983-95.
117. **Maschmeyer G**, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, Franquet T, Blijlevens NMA, Maertens JA; European Conference on Infections in Leukemia (ECIL). Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). *Leukemia* 2019;33:844-62.
118. Klinghammer K, Gauler T, Dietz A, Grünwald V, Stöhlmacher J, Knipping S, Schroeder M, Guntinas-Lichius O, Frickhofen N, Lindeman HW, Fietkau R, Haxel B, Große-Thie C, **Maschmeyer G**, Zipfel M, Martus P, Knoedler M, Keilholz U. Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). *Eur J Cancer* 2019;122:53-60.
119. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikian-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, **Maschmeyer G**, Meis JF, Meletiadiis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M,

- Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild MJGT, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. *Lancet Infect Dis* 2019;19:e405-21.
120. Gudiol C, Albasanz-Puig A, Laporte-Amargós J, Pallarès N, Mussetti A, Ruiz-Camps I, Puerta-Alcalde P, Abdala E, Oltolini C, Akova M, Montejo M, Mikulska M, Martín-Dávila P, Herrera F, Gasch O, Drgona L, Paz Morales H, Brunel AS, García E, Isler B, Kern WV, Morales I, Maestro-de la Calle G, Montero M, Kanj SS, Sipahi OR, Calik S, Márquez-Gómez I, Marin JI, Gomes MZR, Hemmatti P, Araos R, Peghin M, Del Pozo JL, Yáñez L, Tilley R, Manzur A, Novo A, Carratalà J; **IRONIC Study Group**. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection due to *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2020;64:e02494-19.
121. Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, **Maschmeyer G**, **Rothmann F**, Weber T, Müller M, Panse J, Penack O, Schroers R, Braess J, Frickhofen N, Ehl S, Janka G, Lehmborg K, Pletz MW, Hochhaus A, Ernst T, La Rosée P. Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. *J Cancer Res Clin Oncol* 2020;146:1065-77.
122. Ruhnke M, Cornely OA, Schmidt-Hieber M, Alakel N, Boell B, Buchheidt D, Christopeit M, Hasenkamp J, Heinz WJ, Hentrich M, Karthaus M, Koldehoff M, **Maschmeyer G**, Panse J, Penack O, Schleicher J, Teschner D, Ullmann AJ, Vehreschild M, von Lilienfeld-Toal M, Weissinger F, Schwartz S. Treatment of invasive fungal diseases in cancer patients- Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Mycoses* 2020;63:653-82.
123. Pouyiourou M, Meyer A, Stroux A, Viardot A, La Rosée P, **Maschmeyer G**, Kämpfe D, Kahl C, Vucinic V, Monecke A, Hirt C, Weber T, Meissner J, Witzens-Harig M, Böttcher S, Schmalenberg H, Marks R, Prange-Krex G, Kroschinsky F, Hauf E, Keller U, Koch K, Klapper W, Herold M, Scholz CW; East German Study Group for Hematology and Oncology (OSHO). First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis. *Ann Hematol* 2020;99:2821-9.
124. Sinn M, Liersch T, Riess H, Gellert K, Stübs P, Waldschmidt D, Lammert F, **Maschmeyer G**, Bechstein W, Bitzer M, Denzlinger C, Hofheinz R, Lindig U, Ghadimi M, Hinke A, Striefler JK, Pelzer U, Bischoff S, Bahra M, Oettle H. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results. *Eur J Cancer* 2020;138:172-81.
125. Christopeit M, Schmidt-Hieber M, Sprute R, Buchheidt D, Hentrich M, Karthaus M, Penack O, Ruhnke M, Weissinger F, Cornely OA, **Maschmeyer G**. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Hematol* 2021;100:321-36.
126. Wolff D, Herzberg PY, Herrmann A, Pavletic SZ, Heussner P, Mumm F, Höfer C, Hilgendorf I, **Hemmati PG**, Holler E, Greinix H, Mitchell SA. Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. *Bone Marrow Transplant* 2021;56:243-56.
127. **Hemmati PG**, Fischer D, Breywisch F, Wohlfarth S, Kramer M, Paland M, Badakhshi H, Ripberger G, **Maschmeyer G**. Maintaining an adult hematology/oncology service at a

tertiary care center during the SARS-CoV-2 pandemic: an eight-week-experience with a newly implemented procedural plan. *Oncol Res Treat* 2021;44:354-9.

128. Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V; German Pancreatic Cancer Working Group (AIO-PAK) and **NEOLAP investigators**. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. *Lancet Gastroenterol Hepatol* 2021;6:128-38.
129. Bachmann F, Schreder M, Engelhardt M, Langer C, Wolleschak D, Mügge LO, Dürk H, Schäfer-Eckart K, Blau IW, Gramatzki M, Liebisch P, Grube M, Metzler I, Bassermann F, Metzner B, Röllig C, Hertenstein B, Khandanpour C, Dechow T, Hebart H, Jung W, Theurich S, **Maschmeyer G**, Salwender H, Hess G, Bittrich M, Rasche L, Brioli A, Eckardt KU, Straka C, Held S, Einsele H, Knop S. Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM. *Cancers (Basel)* 2021;13:1322.
130. Krüger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, Grobe N, **Maschmeyer G**, Neumann T, Schneidewind L, Niederwieser D, Dölken G, Schmidt CA. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). *Ann Hematol* 2021;100:1569-77.
131. Classen AY, Henze L, von Lilienfeld-Toal M, **Maschmeyer G**, Sandherr M, Graeff LD, Alakel N, Christopeit M, Krause SW, Mayer K, Neumann S, Cornely OA, Penack O, Weißinger F, Wolf HH, Vehreschild JJ. Primary prophylaxis of bacterial infections and *Pneumocystis jirovecii* pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). *Ann Hematol* 2021;100:1603-20.
132. Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, **Maschmeyer G**, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P; German Hodgkin Study Group. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. *Lancet Haematol* 2021;8:e398-409.
133. Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, Hähling D, Hegenbart U, Peter N, Schulze A, Florschütz A, Volker S, Reifenrath K, Zojer N, Junghanss C, Sayer HG, **Maschmeyer G**, Christian S, Hochhaus A, Fischer T, Al-Ali HK, Niederwieser D. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. *Ann Hematol* 2021 Jul 7. doi: 10.1007/s00277-021-04565-1. Epub ahead of print.

II. Übersichtsartikel und Buchbeiträge

1. **Maschmeyer G** (2004): Infektionen bei malignen Erkrankungen. In: Hiddemann W, Bartram CR, Huber H (Hrsg.): Die Onkologie. 1. Aufl., Springer-Verlag Heidelberg-Berlin, S. 781-798
2. **Maschmeyer G** (2004): Infektionen bei Abwehrschwäche (ohne AIDS) beim Erwachsenen. In: Suttrop N, Mielke M, Stück B, Kiehl W (Hrsg.): Infektionskrankheiten. Georg Thieme Verlag Stuttgart, S. 559-571
3. **Maschmeyer G**, Göbel UB (2004): *Stenotrophomonas maltophilia* and *Burkholderia cepacia*. In: Mandell GL, Bennett JE, Dolin R: Principles and Practice of Infectious Diseases, 6th edition, Elsevier Science (USA), Philadelphia, S. 2615-2621
4. **Maschmeyer G**, Ruhnke M (2004): Update on antifungal treatment of invasive *Candida* and *Aspergillus* infections. *Mycoses* 47: 263-276
5. **Maschmeyer G** (2004): Cefepim in der empirischen Initialtherapie bei febrilen neutropenischen Patienten mit malignen Erkrankungen. *Chemother J* 13: 174-180
6. Büchner T, Hiddemann W, Berdel WE, Wörmann B, Löffler H, Schoch C, Haferlach T, Ludwig WD, **Maschmeyer G**, Lengfelder E, Staib P, Andreesen R, Balleisen L, Haase D, Eimermacher H, Schumacher A, Aul C, Rasche H, Uhlig J, Grüneisen A, Reis HE, Hartlapp J, Hirschmann WD, Weh HJ, Pielken HJ, Gassmann W, Sauerland MC, Heinecke A (2004): Acute myeloid leukemia (AML): the role of intensive induction chemotherapy. *Int J Hematol Oncol Bone Marrow Transplant* 1: 1-5
7. Büchner T, Hiddemann W, Berdel WE, Wörmann B, Löffler H, Schoch C, Haferlach T, Ludwig WD, **Maschmeyer G**, Lengfelder E, Staib P, Andreesen R, Balleisen L, Haase D, Eimermacher H, Schumacher A, Aul C, Rasche H, Uhlig J, Grüneisen A, Reis HE, Hartlapp J, Hirschmann WD, Weh HJ, Pielken HJ, Gassmann W, Sauerland MC, Heinecke A (2004): Acute myeloid leukemia (AML): the role of maintenance chemotherapy. *Int J Hematol Oncol Bone Marrow Transplant* 1: 6-11
8. **Maschmeyer G** (2004): Professionelles Infektionsmanagement in der Hämatologie/Onkologie trägt Früchte. *Onkologie heute* 06/2004: 4-5
9. **Maschmeyer G** (2005): Management of vancomycin-resistant enterococci – a Paradigm. *Onkologie* 28: 183-184
10. **Maschmeyer G** (2005) Pathogenic Fungi: Host interactions and emerging strategies for control (book review). *Expert Rev Anti Infect Ther* 3: 7-8
11. **Maschmeyer G**, Glasmacher A (2005): Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. *Mycoses* 48: 227-234
12. **Maschmeyer G**, Haas A, Böhme A (2005): Aktuelle Therapie invasiver Mykosen in der Hämatologie und Onkologie. *Dtsch Med Wschr* 130: 1381-1384
13. Link H, **Maschmeyer G** (2005): Therapie und Prophylaxe von Infektionen bei Neutropenie. In: Schmoll HJ, Höffken K, Possinger K (Hrsg.): Kompendium Internistische Onkologie, 4. Aufl., Springer-Verlag Berlin Heidelberg New York, S. 2088-2131
14. **Maschmeyer G**, Schwarz M (2005): Onkologische Notfälle (R Gucaip, J Dutcher). In: Dietel M, Suttrop N, Zeitz M (Hrsg.): *Harrisons Innere Medizin*, 16. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 617-625

15. Schwarz M, **Maschmeyer G** (2005): Spätfolgen von Krebserkrankungen und ihrer Behandlung (MC Perry, DL Longo). In: Dietel M, Suttorp N, Zeitz M (Hrsg.): *Harrisons Innere Medizin*, 16. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 626-628
16. **Maschmeyer G** (2005): Erkrankungen der Plasmazellen (DL Longo, KC Anderson). In: Dietel M, Suttorp N, Zeitz M (Hrsg.): *Harrisons Innere Medizin*, 16. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 703-709
17. **Maschmeyer G** (2005): Management von Systemmykosen. *Symposium Medical Infektiologie 2005*: 8-11
18. Neuburger S, **Maschmeyer G** (2006): Update on management of infections in cancer and stem cell transplant patients. *Ann Hematol* 85: 345-356
19. **Maschmeyer G** (2006): The changing epidemiology of invasive fungal infections: new threats. *Int J Infect Dis* 27S1: 3-6
20. Genvresse I, **Maschmeyer G** (2006): Chickenpox and zoster in marrow transplant recipients. In: Doerr DW, Gross G (Hrsg.): *Herpes Zoster. Monographs in Virology*, Karger-Verlag, Basel, 2006, Vol. 26, S. 107-116
21. **Maschmeyer G, Haas A** (2006): Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections. *Future Microbiology* 1:365-385
22. **Maschmeyer G** (2006): Infektionsprophylaxe bei Tumorpatienten. 30. Forumband „Fortschritt und Fortbildung in der Medizin“: S. 227-233, Bundesärztekammer 2006
23. **Maschmeyer G** (2006): Behandlung invasiver Pilzinfektionen. *Medizin Forum Aktuell* Nr. 393: 1-2
24. **Maschmeyer G, Haas A** (2006): Infektionen bei immunkompromittierten Patienten. In: Van Aken, Reinhart, Zimpfer, Welte (Hrsg.): *Intensivmedizin*. Georg Thieme Verlag Stuttgart, S. 792-799
25. **Maschmeyer G, Haas A** (2006): Invasive Pilzinfektionen. In: Van Aken, Reinhart, Zimpfer, Welte (Hrsg.): *Intensivmedizin*. Georg Thieme Verlag Stuttgart, S. 786-791
26. **Maschmeyer G, Haas A, Cornely OA** (2007): Invasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients. *Drugs* 2007; 67:1567-601
27. Peters U, **Maschmeyer G** (2007): Fieber und Infektionen. In: Aulbert/Nauck/Radbruch (Hrsg.) *Lehrbuch der Palliativmedizin*, 2. Auflage. Schattauer Verlag Stuttgart, S. 419-428
28. Sandherr M, **Maschmeyer G** (2007): Infektionen in der Onkologie. *Best Practice Onkologie* 2: 47-59
29. **Maschmeyer G, Haas A** (2007): Die Behandlung des Myeloms – heute. *Arzneiverordnung in der Praxis* 34: 63-64
30. **Maschmeyer G, Haas A** (2007): Therapie der febrilen Neutropenie. *OnkoLogisch* 2/2007: 7-9
31. **Maschmeyer G, Haas A** (2008): The epidemiology and treatment of infections in cancer patients. *Int J Antimicrob Agents* 31: 193–197

32. Neuburger S, **Maschmeyer G** (2007): Changing epidemiology and challenges of fungal infections in bone marrow transplantation. *European Infectious Diseases Touch Briefings* 2007: 61-62
33. **Haas A, Maschmeyer G**, Grebner S (2007): Möglichkeiten und Grenzen standardisierter Prozessorganisation im Krankenhaus. *Gesundheits- und Sozialpolitik* 11-12/2007: S. 48-55
34. **Maschmeyer G** (2008): Therapie von Bronchialkarzinomen. *Pharmazeutische Zeitung* 2008: 27-28
35. **Haas A, Maschmeyer G** (2008): Antibiotikatherapie in der Schwangerschaft. *Dtsch Med Wschr* 2008;133:511-515
36. **Maschmeyer G** (2008): Invasive aspergillosis in severely immunosuppressed patients – Significant progress, but many unresolved problems. *Transpl Infect Dis* 2008;10:151-155
37. **Maschmeyer G** (2008): Erkrankungen der Plasmazellen (NC Munshi, DL Longo, KC Anderson). In: Dietel M, Suttorp N, Zeitz M (Hrsg.): *Harrisons Innere Medizin*, 17. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 874-882
38. **Maschmeyer G, Haas A** (2008): Onkologische Notfälle (R Gucalp, J Dutcher). In: Dietel M, Suttorp N, Zeitz M (Hrsg.): *Harrisons Innere Medizin*, 17. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 2130-2141
39. **Maschmeyer G, Rothmann F** (2008): Spätfolgen von Krebserkrankungen und ihrer Behandlung (MC Perry, DL Longo). In: Dietel M, Suttorp N, Zeitz M (Hrsg.): *Harrisons Innere Medizin*, 17. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, e91-95
40. **Maschmeyer G** (2009): Pilzinfektionen. In: Arzneimittelkommission der Deutschen Ärzteschaft (Hrsg.): *Arzneiverordnungen*, 22. Aufl., Medizinische Medien Informations-Verlag Berlin
41. **Maschmeyer G** (2008): Thalidomid-Abkömmling Lenalidomid wirksam bei rezidiviertem oder refraktärem multiplen Myelom. *Arzneiverordnung in der Praxis* 35: 96-97
42. **Maschmeyer G** (2009): Micafungin und Anidulafungin – neue Optionen zur Behandlung von Candidämie und invasiven Mykosen? *Arzneiverordnung in der Praxis* 36: 18-19
43. Sandherr M, **Maschmeyer G** (2008): Antimikrobielle Therapie bei Patienten mit soliden Tumoren und hämatologischen Neoplasien. *Im Focus Onkologie* 10: 54-60
44. **Maschmeyer G**, Sandherr M (2009): Infektionen in der Hämatologie und Onkologie. *Internist* 50: 187-202
45. **Maschmeyer G** (2009): Prevention of mould infections. *J Antimicrob Chemother* 63 Suppl 1: i27-30
46. **Breywisch F, Maschmeyer G** (2009): Allogene und autologe Stammzelltransplantation – eine Übersicht. *Brandenburgisches Ärzteblatt* 19: 16-30
47. **Maschmeyer G**, Calandra T, Singh N, Wiley J, Perfect J (2009): Invasive mould infections: a multi-disciplinary update. *Med Mycol* 2009;47: 571-583

48. **Maschmeyer G, Haas A** (2008): Systemische Mykosen. In: Nowrouzian MR (Hrsg.): Supportive Therapie in der Onkologie (2. Aufl.). Zuckschwerdt Verlag München Wien New York, S. 209-217
49. **Haas A, Maschmeyer G** (2008): Onkologische Notfälle. In: Nowrouzian MR (Hrsg.): Supportive Therapie in der Onkologie (2. Aufl.). Zuckschwerdt Verlag München Wien New York, S. 237-255
50. **Maschmeyer G** (2009): Infektionen bei malignen Erkrankungen. In: Hiddemann W, Bartram CR, Huber H (Hrsg.): Die Onkologie. 2. Aufl., Springer-Verlag Heidelberg-Berlin, S. 768-781
51. Dickerhoff R, von Rücker A, **Maschmeyer G**, Heimpel H (2009): Probleme erwachsener Sichelzellpatienten in Deutschland. Dtsch Med Wochenschr 134: 1179-1184
52. **Maschmeyer G**, Patterson TF (2009): New immunosuppressive agents and risk for invasive fungal infection. Curr Infect Dis Rep 11: 435-438
53. Marr KA, Bow E, Chiller T, **Maschmeyer G**, Ribaud P, Segal B, Steinbach W, Wingard JR, Nucci M (2009): Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 44: 483-487
54. Kommission für Krankenhaushygiene und Infektionsprävention beim Robert-Koch-Institut (Exner M, **Maschmeyer G**, Christiansen B, Engelhart S, Hornei B, Wischniewski N, Simon A) (2010): Anforderungen an die Hygiene bei der medizinischen Versorgung von immunsupprimierten Patienten. Bundesgesundheitsbl 53: 357–388
55. **Maschmeyer G** (2011): Epidemiology of respiratory events in patients with hematological malignancies. In: Azoulay E (Ed.): Pulmonary involvement in patients with hematological malignancies. Springer Verlag Berlin Heidelberg, S. 41-45
56. **Maschmeyer G**, Ljungman P (2011): Infections in patients undergoing hematopoietic stem cell transplantation. In: Safdar A (Ed.): Management of Infections in Cancer Patients. Springer Verlag New York Heidelberg, S. 17-26
57. **Maschmeyer G** (2010): Infektionen bei immunkompromittierten Patienten. In: Van Aken, Reinhart, Zimpfer, Welte (Hrsg.): Intensivmedizin. Georg Thieme Verlag Stuttgart (in Druck)
58. **Maschmeyer G** (2010): Invasive Pilzinfektionen. In: Van Aken, Reinhart, Zimpfer, Welte (Hrsg.): Intensivmedizin. Georg Thieme Verlag Stuttgart (in Druck)
59. **Maschmeyer G** (2010): Aktuelle Richtlinien zur Antimykotika-Prophylaxe. In: Schmitt M (Hrsg.): Antimykotische Prophylaxe bei Neutropenie und Immundefizienz. Uni-Med Verlag (in Druck)
60. **Breywisch F** (2011): Autologe hämatopoetische Stammzelltransplantation: Komplikationen. In: Huber Ch et al (Hrsg.): Hämatopoetische Stammzellen: Grundlagen und Klinische Einsatzgebiete.
61. **Maschmeyer G**, Ruhnke M, Böhme A (2010): Diagnosis and management of fungal infections in hematology and oncology. Hematology Education 4: 262-7
62. **Maschmeyer G** (2011): Invasive fungal disease: better survival through early diagnosis and therapeutic intervention. Expert Rev Anti Infect Ther 9: 279-281

63. Sandherr M, **Maschmeyer G** (2011): Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis – review of the literature. *Eur J Med Res* 16: 139-44
64. Heußel CP, Bialek R, Arnold R, Deja M, Reinke P, **Maschmeyer G** (2011): Komplikationen bei immuninkompetenten Patienten. *Intensivmedizin und Notfallmedizin* 48: 426-431
65. Müller-Löbnitz C, Eder M, Kluge S, Knitsch W, Kuse ER, **Maschmeyer G**, Quintel M, Welte T (2011): Pulmonale Aspergillosen: Konsequenzen der neuen AGIHO-Empfehlungen für die klinische Praxis. *Intensiv- und Notfallbehandlung, Jahrgang 37 - 1. Quartal (30 - 37)*
66. Exner M, Engelhart S, Gebel J, Ilscher C, Pfeifer R, Höller C, Dilloo D, **Maschmeyer G**, Simon A (2011): Hygiene-Tipps für immunsupprimierte Patienten zur Vermeidung übertragbarer Infektionskrankheiten. *Hyg Med* 36: 36-44
67. **Maschmeyer G** (2011): Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic cancer patients. *Curr Infect Dis Rep* 13: 510-6
68. **Maschmeyer G**, Koch K, Jungehülsing M (2011): Kopf-Hals-Tumoren: Interdisziplinäre Therapiekonzepte. *Best Practice Onkologie* 6: 4-20
69. **Rothmann F, Maschmeyer G** (2011): Die Bestimmung der freien Leichtketten (Freelite) und der Immunglobulin-Kappa/Lambda-Subtypen (Hevylite) in der Diagnostik von Plasmazellerkrankungen. *J Lab Med* 35: 271-278
70. Peters U, **Maschmeyer G** (2011): Fieber und Infektionen. In: Aulbert/Nauck/Radbruch (Hrsg.) *Lehrbuch der Palliativmedizin*, 3. Auflage. Schattauer Verlag Stuttgart, S. 410-418
71. **Maschmeyer G** (2011): Hygieneanforderungen in der Hämatologie und Onkologie: Die neue RKI-Richtlinie. *MedReview* 18/2011: 6-7
72. **Maschmeyer G** (2012): Erkrankungen der Plasmazellen (NC Munshi, DL Longo, KC Anderson). In: Dietel M, Suttrop N, Zeitz M (Hrsg.): *Harrisons Innere Medizin*, 18. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 1007-1015
73. **Maschmeyer G** (2012): Onkologische Notfälle (R Gucalp, J Dutcher). In: Dietel M, Suttrop N, Zeitz M (Hrsg.): *Harrisons Innere Medizin*, 18. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 2450-2465
74. **Maschmeyer G** (2012): Spätfolgen von Krebserkrankungen und ihrer Behandlung (MC Perry, DL Longo). In: Dietel M, Suttrop N, Zeitz M (Hrsg.): *Harrisons Innere Medizin*, 18. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 900-905
75. **Maschmeyer G** (2013): Aktuelle Richtlinien zur Antimykotika-Prophylaxe. In: Schmitt M (Hrsg.): *Antimykotische Prophylaxe bei Neutropenie und Immundefizienz*. Uni-Med Verlag Bremen – London – Boston, S. 43-51
76. **Maschmeyer G** (2014): Infektionen bei immunkompromittierten Patienten. In: Van Aken, Reinhart, Welte, Weigand (Hrsg.): *Intensivmedizin*. Georg Thieme Verlag Stuttgart, 3. Auflage, S. 579-587
77. **Maschmeyer G** (2014): Invasive Pilzinfektionen. In: Van Aken, Reinhart, Welte, Weigand (Hrsg.): *Intensivmedizin*. Georg Thieme Verlag Stuttgart, 3. Auflage,
78. Rieger C, Barlow S, **Maschmeyer G** (2014): What's new in diagnosis and antimicrobial therapy of febrile neutropenic patients with lung infiltrates. *Intensive Care Med* 40: 1549-1552

79. **Maschmeyer G**, Rolston KVI (2015): Infections in Hematology. Springer-Verlag Heidelberg New York Dordrecht London.
80. **Maschmeyer G** (2015): Consequences from specific treatment modalities. In: Maschmeyer G, Rolston KVI (eds.): Infections in Hematology. Springer-Verlag Heidelberg New York Dordrecht London, S. 39-47
81. **Maschmeyer G** (2015): Fever of unknown origin: treatment according to risk assessment. In: Maschmeyer G, Rolston KVI (eds.): Infections in Hematology. Springer-Verlag Heidelberg New York Dordrecht London, S. 155-163
82. **Maschmeyer G (2015)**: Pulmonary complications. In: Maschmeyer G, Rolston KVI (eds.): Infections in Hematology. Springer-Verlag Heidelberg New York Dordrecht London, S. 165-185
83. **Maschmeyer G, Breywisch F** (2015): Autologe hämatopoetische Stammzelltransplantation: Komplikationen. In: Herr W et al (Hrsg.): Hämatopoetische Stammzellen: Grundlagen und Klinische Einsatzgebiete. Deutscher Ärzte-Verlag Köln
84. **Maschmeyer G**, Donnelly JP. How to manage lung infiltrates in persons with haematological malignancy outside allogeneic stem cell transplantation. Br J Haematol 2016;173:179-89.
85. Cornberg M, Schlevogt B, Rademacher J, Schwarz A, Sandherr M, **Maschmeyer G** (2016): Spezifische Infektionen bei Organtransplantation. Internist 57: 38-48
86. Sandherr M, Rieger C, **Maschmeyer G** (2016): Prävention viraler Infektionen bei immunsupprimierten Patienten mit soliden Tumoren und hämatologischen Neoplasien. Best Practice Onkologie 11:17-23
87. Simon A, Exner M, **Maschmeyer G** (2016): Infektionen bei Immunsuppression. In: Kramer A, Assadian O, Exner M, Hübner NO, Simon A (Hrsg.): Krankenhaus- und Praxishygiene. 3. Auflage. Urban & Fischer, München, S. 313-318
88. **Maschmeyer G** (2016): Erkrankungen der Plasmazellen (NC Munshi, DL Longo, KC Anderson). In: Dietel M, (Hrsg.): Harrisons Hämatologie und Onkologie, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 290-305
89. **Maschmeyer G** (2016): Onkologische Notfälle (R Gucalp, JP Dutcher). In: Dietel M, (Hrsg.): Harrisons Hämatologie und Onkologie, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 880-899
90. **Maschmeyer G** (2016): Spätfolgen von Krebserkrankungen und ihrer Behandlung (CE Freter, DL Longo). In: Dietel M, (Hrsg.): Harrisons Hämatologie und Onkologie, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 900-909
91. **Maschmeyer G**, Badakhshi H, Jungehülsing M, Tinhofer-Keilholz I (2017): HPV-assoziierte Kopf-Hals-Tumoren: Update 2017. Best Practice Onkologie 12: 130-136
92. Von Lilienfeld-Toal M, **Maschmeyer G** (2018): Challenges in Infectious Diseases for Hematologists. Oncol Treat Res 41: 406-410
93. Blau IW, Heinz WJ, Schwartz S, Lipp HP, Schafhausen P, **Maschmeyer G** (2018): Wichtige Differenzialdiagnosen von Lungeninfiltraten bei hämatologischen Patienten. MMW (in Druck)
94. **Maschmeyer G** (2018): Antimikrobielle Therapie und Prophylaxe. In: Kreuzer KA (Hrsg.) Klinisches Referenzwerk Hämatologie, Georg Thieme Verlag Stuttgart.

95. **Maschmeyer G** (2018): Lungeninfiltrate bei febriler Neutropenie. Journal Onkologie (in Druck)
96. **Hemmati PG** (2018): Allogene Stammzelltransplantation. Klinische Praxis und Perspektiven. Best Practice Onkologie 13: 128-136
97. **Maschmeyer G** (2020): Erkrankungen der Plasmazellen (NC Munshi, DL Longo, KC Anderson). In: Suttorp N et al (Hrsg.): Harrisons Innere Medizin, Thieme-Verlag/ABW Wissenschaftsverlag Berlin, S. 983-994
98. **Maschmeyer G** (2020): Onkologische Notfälle (R Gucaip, JP Dutcher). In: Suttorp N et al (Hrsg.): Harrisons Innere Medizin, Thieme-Verlag/ABW Wissenschaftsverlag Berlin, S. 635-647
99. **Maschmeyer G** (2020): Spätfolgen von Krebserkrankungen und ihrer Behandlung (CE Freter, DL Longo). In: Suttorp N et al (Hrsg.): Harrisons Innere Medizin, Thieme-Verlag/ABW Wissenschaftsverlag Berlin, S. 837-842

III. Publierte Abstrakte

1. **Maschmeyer G** (2004): Gram-positive infections in cancer patients: the role of linezolid. *Ann Hematol* 83 Suppl 1: S44
2. Büchner Th, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, **Maschmeyer G**, Staib P, Balleisen L, Grüneisen A, Aul C, Lengfelder E, Hehlmann R, Kern W, Serve HL, Mesters RM, Eimermacher H, Frickhofen N, Kienast J, Giagounidis A, Sauerland MC, Heinecke A (2004): Subgroup specific therapy effects in AML: AMLCG data. *Ann Hematol* 83 Suppl 1: S100-101
3. **Maschmeyer G** (2004): Management of febrile neutropenic patients with lung infiltrates. *J Cancer Res Clin Oncol* 130 Suppl 1: S201
4. Cornely OA, Reuter S, Maertens J, Arenz D, Franz J, Ullmann AJ, Martino R, Böhme A, Cesaro S, Schiel X, Auner H, Chopra R, Gratwohl A, Jedrzejczak W, Karthaus M, Kiehl MG, Krüger W, **Maschmeyer G**, Nosari A, Silling G (2004): Regimens and outcomes of current approaches to secondary prophylaxis after proven or probable invasive fungal infections. A multinational case registry. *Clin Microbiol Infect* 10 Suppl 3: 41
5. Cornely OA, Böhme A, Reuter S, Reichert D, **Maschmeyer G**, Silling G, Ullmann AJ, Karthaus M, Wacker S, Wassmer G (2004): Efficacy of secondary antifungal prophylaxis and risk factors for breakthrough invasive fungal infection (IFI) after pulmonary IFI in AML patients – results from a multinational case registry. *Onkologie* 27 (Suppl 3): 9
6. Einsele H, Hebart H, Liebisch P, Bargou R, Meisner C, Metzner B, Wandt H, Wolf H, Sezer O, Casper J, Freund M, Pfreundschuh M, Dölken G, **Maschmeyer G**, Grimminger W, Straka C, Trümper L, Kröger N, Hegewisch-Becker S, Müller P, Hertenstein B, Peest D, Frickhofen N, Mitterer M, Coser P, Kanz L, Bensinger SWI (2004): Comparison of two high-dose chemotherapy regimens and autologous stem cell transplantation in patients with de novo multiple myeloma. *Onkologie* 27 (Suppl 3): 34
7. Cornely OA, Böhme A, Reuter S, Reichert D, **Maschmeyer G**, Silling G, Maertens J, Ullmann AJ, Martino R, Karthaus M, Wacker S, Wassmer G (2004): Efficacy of secondary antifungal prophylaxis and risk factors for breakthrough infection after pulmonary IFI in AML patients: a multinational case registry. Abstract M-664, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 2004, p. 410
8. Papp-Vary M, Oertel SHK, **Maschmeyer G**, Riess H (2004): Single dose per cycle pegfilgrastim successfully supports full dose CHOP-21 in patients with post-transplant lymphoproliferative disorders (PTLD). *Blood* 104 (2): 232b
9. Einsele H, Liebisch P, Bargou R, Meisner Ch, Metzner B, Wandt H, Wolf HH, Sezer O, Casper J, Pfreundschuh M, **Maschmeyer G**, Straka Ch, Truemper L, Kroeger N, Mueller P, Hertenstein B, Frickhofen N, Coser P, Bamberg M, Hebart H, Kanz L (2004): Single high-dose chemoradiotherapy versus tandem high dose melphalan followed by auto-SCT for advanced multiple myeloma. Preliminary analysis. *Blood* 104 (1): 156a
10. Kern W, Serve H, Staib P, Kerschgens Ch, Matylis A, Tischmann K, Huber Ch, Hirschmann WD, Eimermacher H, Lange JG, Zumsprekel A, **Maschmeyer G**, Unterhalt M, Ohnesorge J, Sauerland MC, Berdel W, Büchner Th, Haferlach T, Schoch C, Ludwig WD, Hiddemann W (2004): Prognostic impact of cytogenetics and early response and efficacy of sequential high-dose araC and idarubicin (S-HAI) in patients with refractory and relapsed acute myeloid leukemia (AML): Results of a prospective study. *Blood* 104 (1): 248a-249a

11. Einsele H, Liebisch P, Bargou R, Meisner Ch, Metzner B, Wandt H, Wolf HH, Sezer O, Casper J, Freund M, Pfreundschuh M, Doelken G, **Maschmeyer G**, Grimminger W, Straka C, Truemper L, Kroeger N, Hegewisch-Becker S, Müller R, Hertenstein B, Peest N, Frickhofen N, Mitterer M, Coser P, Hebart H, Bensinger W (2005): Intensified conditioning therapy followed by a single auto-PBSCT versus tandem high-dose melphalan: preliminary analysis. *Bone Marrow Transplant* 35 Suppl 2: S48
12. **Maschmeyer G** (2005): State of the art: antifungal therapy in cancer patients. *Mycoses* 48 Suppl 2: 7
13. Cornely OA, **Maschmeyer G**, Cesaro S, Arenz D, Effelsberg J, Eimermacher H, **Haas A**, Maertens J, Martino R (2005): Secondary prophylaxis after invasive fungal infection of the central nervous system or retinitis. *Mycoses* 48 Suppl 2: 57
14. Cornely OA, Reichert D, Böhme A, Silling G, Reuter S, Martino R, Cesaro S, **Maschmeyer G**, Buchheidt D, Maertens J, Gratwohl A, Kiehl M, Effelsberg J, Chopra R, Novo A, Penack O, Eimermacher H, **Haas A**, Heinz W, Jedrzejcack W, Schiel X, Südhoff T (2005): Voriconazole as secondary prophylaxis after invasive fungal infection. *Onkologie* 28 Suppl 3: 108
15. **Haas A**, Pasold R, Hierholzer J, **Maschmeyer G** (2005): Cure of cerebral aspergillosis in AML folloed by intensive radiochemotherapy and autologous stem cell support – case report. *Onkologie* 28 Suppl 3: 108
16. **Gerhardt A**, Sogalla C, Lobeck H, Fleige B, Stein H, **Maschmeyer G** (2005): Excess leukocytosis resulting from undifferentiated hepatic cancer. *Onkologie* 28 Suppl 3: 162
17. Bohlius J, Böhme A, Penack O, Engert A, Cornely OA, **Maschmeyer G** (2005): Management of infections with hematopoietic growth factors. *Onkologie* 28 Suppl 3: 257
18. **Maschmeyer G** (2006): Defining clinical failure for salvage studies. *Proceedings of 2nd Advances Against Aspergillosis, Athens, February 22-25, 2006*, S. 37
19. Strohscheer I, Bachmann F, **Maschmeyer G**, Samonigg H (2006): Retrospektive Auswertung des Einsatzes von Antibiotika auf der Palliativstation. *Palliativmedizin* 7: S102
20. Gökbüget N, Arnold R, Böhme A, Bartram C, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig W, **Maschmeyer G**, Messerer D, Rieder H, Thiel E, Hoelzer D (2006): Outcome of adult patients with relapsed acute T-lymphoblastic leukemia. *Onkologie* 29 (Suppl 3): 7
21. **Maschmeyer G** (2007): Update on the epidemiology of infections in cancer patients. *Clin Microbiol Infect* 13 Suppl 1: S84
22. **Maschmeyer G** (2007): Fungal infections in critically ill ICU patients. *Infection* 35 Suppl II: 37
23. **Maschmeyer G** (2007): How helpful are diagnostic techniques today? *Onkologie* 30 Suppl 3: 15
24. Gökbüget N, Arnold R, Böhme A, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig W, **Maschmeyer G**, Messerer D, Rieder H, Thiel E, Hoelzer D for the German Multicenter Study Group dor Adult ALL (GMALL) (2007): Improved outcome in high-risk and very high-risk ALL treated according to the GMALL protocol 07/2003. *Onkologie* 30 Suppl 3: 44

25. **Haas A, Maschmeyer G** (2007): How can professional work of oncologists become more efficacious in times of increased competition between hospitals? *Onkologie* 30 Suppl 3: 169
26. **Gerhardt A, Sogalla C, Lobeck H, Horny HP, Feller AC, Sotlar K, Arnold R, Maschmeyer G** (2007): Systemic mastocytosis associated with clonal haematologic non-mast cell-lineage disease after successful chemotherapy of AML with translocation t(8;21). *Onkologie* 30 Suppl 3: 221
27. **Maschmeyer G** (2007): New immunosuppressive agents as risk factors for fungal infections. *J Chemother* 19 Suppl 3: 29 (abstr M3)
28. Gökbüget N, Arnold R, Böhme A, Bartram C, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig W, **Maschmeyer G**, Messerer D, Rieder H, Thiel E, Hoelzer D (2007): Outcome of adult patients with relapsed acute T-lymphoblastic leukemia can be improved with sequential salvage therapies and SCT in second CR. *Haematologica* 92 (Suppl 2): 10
29. Gökbüget N, Arnold R, Böhme A, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig WD, **Maschmeyer G**, Messerer D, Rieder H, Thiel E, Hoelzer D (2007): Improved outcome in high-risk and very high-risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07/2003. *Blood* 110:11a (abstr 12)
30. Knop S, Bauer K, Hebart H, Wandt H, Trümper L, Liebisch P, **Maschmeyer G**, Peest D, Wolf HH, Kröger N, Straka C, Pfreundschuh M, Coser P, Meisner C, Kanz L, Einsele H (2007): A randomized comparison of total-marrow irradiation, busulfan and cyclophosphamide with tandem high-dose melphalan in patients with multiple myeloma. *Blood* 110:223a (abstr 728)
31. Vehreschild J, Sieniawski M, Reuter S, Reichert D, Maertens J, Böhme A, Silling G, Martino R, **Maschmeyer G**, Ullmann A, Cornely O (2008): Efficacy of caspofungin compared to itraconazole as secondary antifungal prophylaxis: a multinational case registry. *Bone Marrow Transplant*;41Suppl1:S285
32. **Maschmeyer G** (2008): Fungal infections after transplantation. *Int J Med Microbiol* 298S2:107
33. Krüger WH, Schüler F, Niederwieser D, Basara N, Sayer H, **Maschmeyer G, Haas A, Kiefer T, Neumann T, Dölken G** (2008): Treatment of mantle cell lymphoma by allogeneic stem cell transplantation – a preliminary report from the trial #060 and #074 of the East German Study Group for Hematology and Oncology (OSHO). *Onkologie* 31Suppl2:27
34. Vehreschild J, Sieniawski M, Reuter S, Reichert D, Maertens J, Böhme A, Silling G, Martino R, **Maschmeyer G**, Rüping MJGT, Ullmann AJ, Cornely OA (2008): Efficacy of caspofungin compared to itraconazole as secondary antifungal prophylaxis: a multinational case registry. *Onkologie* 31Suppl2:29
35. **Maschmeyer G, Fritz L**, Böhme A, Penack O, Schwerdtfeger R, Buchheidt D, Ludwig WD, Neuburger S (2008): Well-fitting masks for prevention of invasive aspergillosis in high-risk neutropenic patients. *Onkologie* 31Suppl2:229
36. **Maschmeyer G, Fritz L**, Neuburger S, Böhme A, Penack O, Schwerdtfeger R, Buchheidt D, Ludwig W (2008): Well-fitting masks for prevention of invasive aspergillosis in high-risk neutropenic patients. 48th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Infectious Diseases Society of America (IDSA) Annual Conference, Washington DC (USA), October 25-28, 2008, abstract #K-4101

37. Büchner T, Berdel WE, Haferlach C, Schnittger S, Haferlach T, Serve H, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Mesters R, Volpert S, Staib P, Grüneisen A, Kern W, Reichle A, Ludwig WD, **Maschmeyer G**, Balleisen L, Eimermacher H, Aul C, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Koepcke W, Krug UO, Sauerland MC, Heinecke A, Woermann BJ, Hiddemann W (2008): Older age is an independent risk factor in AML. Abstracts of the 50th Annual Meeting of the American Society of Hematology, #555; Blood 112Suppl: 207
38. Becker C, Krahl R, Schulze A, **Maschmeyer G**, Junghanß C, Franke A, Peter N, Haenel M, Wedding U, Wolf HH, Haehling D, Meran J, Doelken G, Kaempfe D, Kettner E, Grobe N, Florschuetz A, Kreibich U, Schirmer V, Ittel T, Schulze M, Huhn R, Zschuppe E, Opitz B, Assmann M, Hasenclever D, Poenisch W, Helbig W, Niederwieser DW (2008): Ten year follow up analysis of the OSHO phase III trial (AML 96) comparing different application modes of AraC in patients below 60 years with acute myeloid leukemia (AML): No impact of araC-application mode on remission rate, toxicity, disease-free survival or overall survival. Abstracts of the 50th Annual Meeting of the American Society of Hematology, #2966; Blood 112 Suppl: 1019
39. Krüger W, Basara N, Schüler F, Niederwieser D, Behre G, Grobe N, Sayer H, **Maschmeyer G**, **Haas A**, Kiefer T, Neumann T, Dölken G (2009): Treatment of mantle cell lymphoma by allogeneic stem cell transplantation – a preliminary report from the trials #060 and #074 of the East German Study Group for Haematology and Oncology (OSHO). Abstracts of the 14th Congress of the European Hematology Association, Berlin 4-7 June, 2010, Haematologica 94s2:291 (abstract #714)
40. Rüping MJGT, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C, Beisel C, Herbrecht R, Silling G, Roth Y, Ullmann AJ, Borchert K, Egerer G, Maertens J, **Maschmeyer G**, Simon A, Wattad M, Fischer G, Vehreschild JJ, Cornely OA (2009): Forty-one cases of invasive zygomycosis from a global clinical registry. Mycoses 52 Suppl1: 22;abstr #O2.3
41. Krüger W, Basara N, Hirt C, Niederwieser D, Behre G, Grobe N, Sayer H, **Maschmeyer G**, **Haas A**, Kiefer T, Neumann T, Dölken G (2009): Treatment of mantle cell lymphoma by allogeneic stem cell transplantation – a report from the ongoing trials #060 and #074 of the East German Study Group for Haematology and Oncology (OSHO). Onkologie 32(suppl 4):30 (abstr #P147)
42. Jäkel N, Junghanss C, **Maschmeyer G**, Krahl R, Hoppe G, Eisfeld AK, Lange T, Niederwieser D, Al-Ali HK (2009): Azacitidine in newly-diagnosed and refractory/relapsed AML not eligible for or resistant to chemotherapy: a multi-center phase I/II-study of the East German Haematology and Oncology Study Group (OSHO). Onkologie 32(suppl 4):113 (abstr #P430)
43. Knop S, Liebisch P, Kropff M, Wandt H, Mügge LO, Kröger N, Engelhardt M, Jung W, Wolf HH, Metzner B, Ostermann H, Hart C, Hertenstein B, Kaufmann M, Gramatzki M, Dölken G, Rösler W, Schmitz N, Pfreundschuh M, Fischer T, Heidemann E, Hess G, Gollasch H, **Maschmeyer G**, Weisel K, Bentz M, Kahl C, Dechow T, Brugger W, Jäger E, Kiani A, Salwender H, Sezer O, Simon JP, Straka C, Fingerle-Rawson G, Einsele H (2009): Bortezomib, iv cyclophosphamide and dexamethasone as induction therapy in newly diagnosed multiple myeloma: update on the interim results with 300 patients of the German DSMM XIa trial. Onkologie 32(suppl 4):82 (abstr #V333)
44. Rüping MJ, Vehreschild JJ, Heinz W, Rickerts V, Lass-Flörl C, Groll AH, Ullmann A, Maertens J, Herbrecht R, Kindo A, Roth Y, Wattad M, Egerer G, **Maschmeyer G**, Simon A, Borchert K, Cornely OA (2009): Under the Fungiscope: 41 patients with invasive zygomycosis. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract #M-1049

45. **Maschmeyer G** (2009): Prophylaxis, empirical, preemptive therapy in presumed aspergillosis in hematological patients: Which strategy? *Mycoses* 52 Suppl1: 5-6;abstr #W05.1
46. **Maschmeyer G** (2009): How one manages IMIs in the setting of continuous immune suppression. Abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA), #87
47. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Bargou RC, Metzner B, Peest D, Aulitzky WE, Wandt H, Sezer O, Hentrich M, Ostermann H, Peschel C, Hess G, Hertenstein B, Freund M, Kropff MH, Wolf HH, Jung W, Frickhofen N, **Maschmeyer G**, Mergenthaler HG, Heidemann E, Kröger N, Straka C, Engel C, Kanz L, Meisner C, Einsele H (2009): Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma – an interim analysis of the German DSMM V trial. Abstracts of the 51st Annual Meeting of the American Society of Hematology, #51; *Blood* 2009;114:27
48. Einsele H, Liebisch P, Langer C, Kropff M, Wandt H, Jung W, Kröger N, Engelhardt M, Ostermann H, Mügge LO, Wolf HH, Hart C, Metzner B, Kaufmann M, Gramatzki M, Hertenstein B, Fischer T, Weisel K, Dölken G, Brugger W, Gollasch H, **Maschmeyer G**, Pfreundschuh M, Schmitz N, Sezer O, Heidemann E, Jäger E, Kahl C, Kiani A, Dechow T, Rösler W, Simon JP, Dürk H, Pflüger KH, Bentz M, Hess G, Mergenthaler HG, Straka C, Hempel D, Salwender HJ, Fingerle-Rowson G, Knop S (2009): Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial). Abstracts of the 51st Annual Meeting of the American Society of Hematology, #131; *Blood* 2009;114:59
49. Büchner T, Berdel WE, Haferlach C, Schnittger S, Haferlach T, Serve H, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Mesters R, Volpert S, Staib P, Grüneisen A, Kern W, Reichle A, Ludwig WD, **Maschmeyer G**, Balleisen L, Eimermacher H, Aul C, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Köpcke W, Krug UO, Sauerland MC, Heinecke A, Woermann BJ, Hiddemann W (2009): Long-term results in patients with acute myeloid leukemia (AML): the influence of high-dose AraC, G-CSF priming, autologous transplantation, prolonged maintenance, age, history, cytogenetics, and mutation status. Data of the AMLCG 1999 Trial. Abstracts of the 51st Annual Meeting of the American Society of Hematology, #485; *Blood* 2009;114:200
50. Rummel MJ, Niederle N, **Maschmeyer G**, Banat A, von Gruenhagen U, Losem C, Heil G, Welslau M, Balsler C, Kaiser U, Ballo H, Weidmann E, Duerk HA, Kofahl-Krause D, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2009): Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StIL (Study Group Indolent Lymphomas, Germany). Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 405; *Blood* 2009;114:168
51. Zohren F, Bruns I, Barth J, Pechtel S, Fenk R, Schroeder T, Czibere AG, **Maschmeyer G**, Kofahl-Krause D, Heil G, Niederle N, Losem C, Welslau M, Germing U, Kronenwett R, Haas R, Rummel MJ, Kobbe G (2009): Quantitative real-time PCR of peripheral blood t(14;18) positive cells predicts treatment response and long-term outcome in patients with follicular lymphoma. Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 441, *Blood* 2009;114:183
52. Goekbuget N, Brueggemann M, Arnold R, Bartram CR, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig WD, **Maschmeyer G**, Messerer D, Raff T, Rieder H, Thiel E, Hoelzer D (2009): New definition of treatment response in adult acute lymphoblastic leukemia (ALL): use of molecular markers for minimal residual disease (MRD). Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 90, *Blood* 2009;114:42

53. Schueler F, Basara N, **Maschmeyer G**, Fischer T, Herold M, Sayer HG, Wolf HH, Kreibich U, Haehling D, Doelken G, Junghanss C, Grobe N, Krahl R, Al-Ali HK, Poenisch W, Niederwieser D (2009): Reduction of relapse incidence and improvement of leukemia free survival by allogeneic stem cell transplantation in patients with AML and normal karyotype irrespective of the FLT3-ITD status. Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 1612, Blood 2009;114:644
54. Cross M, Jaekel N, Krahl R, Junghanss C, **Maschmeyer G**, Tran T, Hoppe G, Niederwieser D, Al-Ali HK (2009): Low levels of global (LINE) and CDH13 methylation at diagnosis and rapid clearance of marrow blasts correlate with a better haematological response to azacitidine in patients with newly diagnosed and refractory/relapsed AML not eligible for or resistant to chemotherapy: A Multi-Centre Phase I/II-Study of the East German Haematology and Oncology Study Group (OSHO). Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 2642, Blood 2009;114:1036-7
55. Burchardt CA, Brugger W, **Maschmeyer G**, Kofahl-Krause D, Fischer L, Roller F, Barth J, Rummel MJ (2009): Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III study of B-R vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study Group Indolent Lymphomas, Germany). Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 2679, Blood 2009;114:1048-9
56. Schüler F, **Maschmeyer G**, Fischer T, Herold M, Sayer HG, Wolf HH, Kreibich U, Hähling D, Dölken G, Junghanss C, Grobe N, Krahl R, Lange T, Al-Ali HK, Basara N, Pönisch W, Niederwieser D for the East German Study Group Hematology and Oncology (OSHO) (2010): Allogeneic stem cell transplantation reduces the relapse incidence in patients with AML and normal karyotype independently of the FLT3-ITD status. Abstracts of the 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, Wien, 21.-24.3.2010; #O-234
57. Herold M, **Maschmeyer G**, Lakner V, Dölken G, Ehninger G, Hänel M, Rohrberg R, Hochhaus A, Neubauer A, Fischer L, von Grünhagen U, Hahnfeld S, Hoffmann F, Wußling M, Stein W, Kettner E, Hähling D (2010): Sustained survival advantage after a median follow-up of 5 years for immunochemotherapy (R-MCP) versus chemotherapy alone (MCP) in advanced follicular lymphoma – update of the OSO#39 trial. Abstracts of the 15th Congress of the European Hematology Association, Barcelona, June 10-13, 2010, Haematologica 95s2:239 (abstr. #0575)
58. Niederwieser D, Schueler F, Hegenbart U, **Maschmeyer G**, Fischer T, Junghanss C, Wolf H, Sayer HG, Kreibich U, Dölken G (2010): Improvement of leukemia-free survival and reduction of relapse incidence by allogeneic stem cell transplantation in elderly patients with AML irrespective of the FLT3-ITD and NPM status except NPM+FLT3-. Abstracts of the 46th Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, June 4-8, 2010, J Clin Oncol 28 (15S):489s, abstr #6509
59. **Maschmeyer G**, Heinz W, Hertenstein B, Horst HA, Requadt C, Wagner T, Ruhnke M (2010): Immediate versus deferred antifungal treatment in high-risk patients with febrile neutropenia. Results from the randomized, double-blind, placebo-controlled, multicenter IDEA Study. 50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Boston (USA), September 12-15, 2010, abstract #M-1061
60. **Maschmeyer G** (2010): "Fever of unknown origin" – mit Anamnese und Befund zur Differentialdiagnose. Anästh Intensivmed 51:S694
61. **Maschmeyer G** (2010): What have we learned about systemic antifungals currently available on the market? Abstracts of the 2nd Workshop of the European Confederation of Medical Mycology (ECMM), Milan 23-25 September 2010, p.64

62. **Maschmeyer G** (2010): Central venous catheter-associated infections. *Onkologie* 2010;33(suppl 6):4
63. Herold M, **Maschmeyer G**, Lakner V, Dölken G, Ehninger G, Hänel M, Rohrberg R, Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO) (2010): Survival advantage for immunochemotherapy (R-MCP) over chemotherapy (MCP) alone in advanced follicular lymphoma after a median follow up of 5 years – updated results of the OSHO#39 study. *Onkologie* 2010;33(suppl 6):132
64. Zohren F, Bruns I, Barth J, Pechtel S, Fenk R, Schroeder T, **Maschmeyer G**, Kofahl-Krause D, Niederle N, Heil G, Losem C, Welslau M, Germing U, Kronenwett R, Rummel MJ, Haas R, Kobbe G (2010): Quantitative real-time PCR of circulating bcl2/IgH+ cells at diagnosis, after therapy and during follow-up predicts long-term outcome and imminent relapse in patients with follicular lymphoma. *Onkologie* 2010; 33(suppl 6):158
65. Gökbüget N, Brüggemann M, Arnold R, Bartram CR, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig WD, **Maschmeyer G**, Messerer D, Raff T, Rieder H, Serve H, Thiel E, Hoelzer D (2010): Definition of molecular remission in adult acute lymphoblastic leukemia based on minimal residual disease. *Onkologie* 2010; 33(suppl 6):213
66. Rummel MJ, Tenzer A, Niederle N, Losem C, Balsler C, Balló HE, Welslau M, Grünhagen U, Brugger W, **Maschmeyer G**, Matzdorff AC, Ganser A, Weidmann E, Heil G, Hinke A, Barth J (2010): No elevated rates of treatment-related myelodysplastic syndromes and second solid tumors following therapy with bendamustine compared with other anti-lymphoma regimes for low-grade Non-Hodgkin's lymphoma. Abstracts of 52nd Annual Meeting of the American Society of Hematology, Orlando FL, December 4-7, 2010, abstr #3090
67. **Maschmeyer G** (2011): Is it time to switch from empirical to preemptive treatment of IFI? *Ann Hematol* 90(suppl 1): S32
68. Niederwieser D, **Maschmeyer G**, Fischer T, Uharek L, Kortmann R, Hegenbart U, Dreger P, Herold M, Sayer HG, Wolf H, Kreibich U, Hähling D, Junghanss C, Grobe N, Krahl R, Lange T, Al-Ali HK, Pönisch W, Nehring C, Doelken G (2011) Relapse incidence and leukemia-free survival (LFS) in patients (pts) older than age 60 with AML undergoing stem cell transplantation: A report of the East German Study Group Hematology and Oncology (OSHO). Abstracts of the 47th Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, June 3-7, 2011, *J Clin Oncol* 29 (suppl), abstr #6523
69. Lange T, Niederwieser D, Hoffmann V, Pffirmann M, **Maschmeyer G**, Fischer T, Herold M, Sayer HG, Junghanss C, Krahl R, Al-Ali HK, Pönisch W, Vucinic V, Doelken G, Sauerland MC, Heinecke A, Hoelzer D, Heilmann R, Berdel WE, Büchner T (2011): Intergroup study in elderly patients with AML to compare complete remission rate and overall survival after intermediate-dose or low-dose AraC. Abstracts of the 47th Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, June 3-7, 2011, *J Clin Oncol* 29 (suppl), abstr #6618
70. Reinwald M, Spiess B, Heinz W, Vehreschild JJ, Lass-Flörl C, Kiehl M, Schultheis B, Krause SW, Wolf HH, **Maschmeyer G**, Hofmann WK, Buchheidt D (2011): Diagnosing Pulmonary Aspergillosis in Patients with Hematologic Malignancies: Prospective evaluation of an aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. 51st Annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Chicago (USA), September 17-20, 2011, abstract #M-486
71. Vehreschild MJ, Meissner A, Cornely OA, **Maschmeyer G**, Neumann S, v Lilienfeld-Toal M, Karthaus M, Wattad M, Staib, Hellmich M, Christ H, Vehreschild JJ (2011): A clinical definition for chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. 51st Annual Interscience Conference of Antimicrobial

Agents and Chemotherapy (ICAAC), Chicago (USA), September 17-20, 2011, abstract #K-1124

72. Krüger WH, Basara N, Hirt C, Niederwieser D, Behre G, Grobe N, Sayer H, **Maschmeyer G, Haas A**, Fischer T, Kiehl M, Busemann C, Dölken G (2011): Treatment of mantle cell lymphoma by allogeneic stem cell transplantation – Results from the prospective trials #060 and #74 of the East German Study Group for Hematology and Oncology (OSHO). *Onkologie* 2011;34(suppl 6):70-71
73. **Rothmann F**, Rohland A, **Maschmeyer G** (2011): Clinical usefulness of the Hevylite assay in patients with monoclonal gammopathy. *Onkologie* 2011;34(suppl 6): 157-158
74. Gökbüget N, Stanze D, Arnold R, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig WD, **Maschmeyer G**, Messerer D, Rieder H, Thiel E, Serve H, Hoelzer D, German Multicenter Study Group for Adult ALL (GMALL) (2011): Treatment of relapsed acute lymphoblastic leukemia (ALL): improved results in GMALL studies but optimisation is an ongoing challenge. *Onkologie* 2011;34(suppl 6): 17
75. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Bargou RC, Metzner B, Dölken G, Peest D, Aulitzky W, Bunjes D, Straka C, Wandt H, Sezer O, Hentrich M, Ostermann H, Dechow T, Heß G, Hertenstein B, Freund M, Kropff M, Wolf H, Jung W, Frickhofen N, **Maschmeyer G**, Mergenthaler H, Kanz L, Meisner C, Einsele H, Deutsche Studiengruppe Multiples Myelom (DSMM) (2011): Up front allogeneic stem cell transplant is superior to tandem high-dose melphalan in cytogenetically defined ultra high-risk myeloma. *Onkologie* 2011;34(suppl 6): 199-200
76. Reinwald M, Spiess B, Heinz W, Vehreschild JJ, Lass-Flörl C, Kiehl M, Schultheis B, Krause SW, Wolf HH, **Maschmeyer G**, Hofmann WK, Buchheidt D (2011): Prospective multicenter evaluation of an aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples of patients with hematologic malignancies for diagnosing pulmonary aspergillosis. *Onkologie* 2011;34(suppl 6): 255
77. Vehreschild M, Meissner A, Cornely O, **Maschmeyer G**, Neumann S, v Lilienfeld-Toal M, Karthaus M, Wattad M, Staib, Vehreschild JJ (2011): A clinical definition for early neutropenic enterocolitis predicts death. *Onkologie* 2011;34(suppl 6):302-303
78. Niederwieser D, Verdonck LF, Cornelissen JJ, Cross M, Krahl R, Lange T, Vucinic V, Franke G, Al-Ali HK, Ossenkuppele G, **Maschmeyer G**, Doelken G, Freund M, Peter N, Boogaerts M, Gratwohl A, Schouten HC, Löwenberg B (2011): Long term outcome after low dose TBI based conditioning hematopoietic stem cell transplantation from related and unrelated donors for older patients with AML. Abstracts of 53rd Annual Meeting of the American Society of Hematology, San Diego CA, December 10-13, 2011, abstr #2030
79. Goekbüget N, Stanze D, Arnold R, Brueggemann M, Fietkau R, Freund M, Ganser A, Ludwig WD, **Maschmeyer G**, Raff T, Rieder H, Thiel E, Serve H, Kneba M, Hoelzer D (2011): Overall outcome of relapsed acute lymphoblastic leukemia can be improved by stem cell transplantation and early treatment in stage of molecular relapse. Abstracts of 53rd Annual Meeting of the American Society of Hematology, San Diego CA, December 10-13, 2011, abstr #250
80. Krüger WH, Hirt C, Basara N, Niederwieser D, Behre G, Grobe N, Sayer HG, **Maschmeyer G**, Fischer T, Kiehl M, Busemann C, Doelken G (2011): Allogeneic stem cell transplantation of mantle cell lymphoma – results of the prospective trials OSHO #060 and OSHO #074. Abstracts of 53rd Annual Meeting of the American Society of Hematology, San Diego CA, December 10-13, 2011, abstr #2014
81. Rummel MJ, Niederle N, **Maschmeyer G**, Banat AG, von Gruenhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balsler C, Kaiser U, Weidmann E, Duerk HA, Ballo

- H, Stauch M, Barth J, Hinke A, Brugger W, Study Group Indolent Lymphomas (StiL) (2012): Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. Abstracts of the 48th Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, June 1-5, 2012, J Clin Oncol 30, 2012 (suppl; abstr 3)
82. Schenk T, **Maschmeyer G**, Sayer HG, Kentouche K, Pletz M, Janka G, Lehmborg K, Hochhaus A, La Rosée P (2012): Adults with hemophagocytic lymphohistiocytosis (HLH): an underestimated diagnosis? Initiative for an adult HLH registry. *Onkologie* 35 (suppl 6): 22 (abstr #V86)
83. **Maschmeyer G** (2012): Pulmonary complications in hematologic patients: fungal infections. *Onkologie* 35 (suppl 6): 39 (abstr #V140)
84. Knödler M, Dietz A, Gauler T, Stoehlmacher J, Grünwald V, Rethwisch V, Frickhofen N, Haxel B, Schroeder M, Knipping S, **Maschmeyer G**, Guntinas-Lichius O, Keilholz U (2012): An analysis of toxicity in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving cetuximab, fluorouracil and cisplatin alone or with docetaxel in a phase II clinical trial (CeFCiD). *Onkologie* 35 (suppl 6): 153 (abstr #P514)
85. Reiser M, Hensel M, Hoesl M, Janssen J, Jentsch-Ullrich K, Koenigsmann M, Lück A, Schwarzer A, Tschechne B, Hechenbichler K, Kellershohn K, **Maschmeyer G** (2012): Non-interventional study of rituximab in the treatment of chronic lymphocytic leukemia (CCL NIS): first interim results. *Onkologie* 35 (suppl 6): 217 (abstr #P723)
86. Rummel MJ, Niederle N, **Maschmeyer G**, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balsler C, Kaiser U, Weidmann E, Dürk HA, Ballo H, Strauch MB, Roller F, Barth J, Hinke A, Burchardt AC, Brugger W (2012): Subanalysis of the StiL NHL 1-2003 study: achievement of complete response with bendamustine-rituximab and CHOP-R in the first-line treatment of indolent and mantle cell lymphomas results in superior survival compared to partial response. Abstracts of 54th Annual Meeting of the American Society of Hematology, Atlanta GA, December 8-11, 2012, abstr #2724
87. Schenk T, **Maschmeyer G**, **Rothmann F**, Weber T, Christopeit M, Penack O, Goy D, Panse J, Janka G, Hochhaus A, La Rosée P (2012): Adult patients with hemophagocytic lymphohistiocytosis (HLH) in Germany: a retrospective multicenter case study of 20 patients. Abstracts of 54th Annual Meeting of the American Society of Hematology, Atlanta GA, December 8-11, 2012, abstr #3271
88. Niederwieser D, Hoffmann VS, Krahl R, Berdel WE, Sauerland MC, Hiddemann W, Hegenbart U, Wörmann BJ, Krug U, Pönisch W, Vucinic V, Hebenstreit K, Cross M, Niederwieser C, Pfirrmann M, Schulze A, Krämer A, **Maschmeyer G**, Freund M, Scholl S, Heinicke T, Hähling D, Wolf HH, Büchner T (2012): Factors influencing complete remission rate in patients \geq 60 years with acute myeloid leukemia (AML): report from the German AML Intergroup study. Abstracts of 54th Annual Meeting of the American Society of Hematology, Atlanta GA, December 8-11, 2012, abstr #128
89. **Maschmeyer G** (2013): Lungenkarzinome. *Pharmazeutische Zeitung* 2013, S. 18-19
90. Knödler M, Dietz A, Gauler TG, Grünwald V, Stoehlmacher J, Knipping S, Guntinas-Lichius O, Frickhofen N, Schroeder M, **Maschmeyer G**, Rethwisch V, Haxel B, Keilholz U (2013): Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Interim results of a randomized phase II clinical trial (CeFCiD). *J Clin Oncol* 31 (suppl): # e17021

91. **Maschmeyer G** (2013): Management of breakthrough invasive fungal infections. *Mycoses* 56 (Suppl. 3): 38-39
92. Knoedler M, Dietz A, Gauler TG, Stoehlmacher-Williams J, Gruenwald V, Rethwisch V, Frickhofen N, Haxel B, Schroeder M, Knipping S, **Maschmeyer G**, Guntinas-Lichius O, Keilholz U (2013): Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCID). *Onkologie* 36 (suppl 7): 94, abstr # 349
93. **Rothmann F, Maschmeyer G** (2013): Heavylite in the differential diagnosis of hypergammaglobulinemia – A case report. *Onkologie* 36 (suppl 7): 156-157, abstr #537
94. Keilholz U, Gauler TC, Dietz A, Gruenwald V, Stoehlmacher-Williams J, Knipping S, Schroeder M, Guntinas-Lichius O, Frickhofen N, Lindemann HW, Fietkau R, Haxel B, Junghanss C, **Maschmeyer G**, Zipfel M, Martus P, Knoedler MK (2014): Cetuximab, fluorouracil, and cisplatin alone or with docetaxel for recurrent/metastatic head and neck cancer (HNSCC): First analysis of AIO trial # 1108. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 6018)
95. Dietz A, Flentje M, Hagen R, Bockmuehl U, Koelbl O, Schilling V, **Maschmeyer G**, Schroeder U, Sittel C, Goerner M, Lenarz T, Klusmann JP, Guntinas-Lichius O, Rudack C, Reinisch S, Foerg T, Westhofen M, Welkoborsky HJ, Esser D, Keilholz U (2014): Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-fluorouracil (F) (TPF), or TP followed by concomitant boost radiotherapy with or without cetuximab for functional organ preservation of resectable laryngeal and hypopharyngeal cancer: First results of the phase II randomized DeLOS-II study. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 6016)
96. Knoedler M, Gauler T, Dietz A, Grünwald V, Stoehlmacher-Williams J, Knipping S, Schroeder M, Guntinas-Lichius O, Frickhofen N, Lindemann HW, Fietkau R, Haxel B, Junghanss C, **Maschmeyer G**, Zipfel M, Martus P, Keilholz U (2014): Cetuximab, fluorouracil and cisplatin alone or with docetaxel for recurrent/metastatic head and neck cancer. Final analysis of AIO trial #1108 CeFCID. *Oncol Res Treat* 37 (suppl 5): 118, abstr # 395
97. Schenk T, Janka G, Lehmsberg K, **Maschmeyer G**, Ehl S, Warnatz K, Brunkhorst F, Hochhaus A, La Rosée P (2014): A registry for adult patients with hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome: call for interdisciplinary patient registration. *Oncol Res Treat* 37 (suppl 5): 78, abstr # 255
98. **Maschmeyer G** (2014): Evidence-based guideline on diagnosis and treatment of neutropenic patients with lung infiltrates. *Oncol Res Treat* 37 (suppl 5): 36, abstr # 134
99. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Metzner B, Peest D, Aulitzky W, Bunjes DW, Straka C, Fischer T, Wandt H, Sezer O, Hentrich M, Ostermann H, Peschel C, Hess G, Hertenstein B, Freund M, Kropff MH, Wolf HH, Jung WE, Frickhofen N, Bargou RC, **Maschmeyer G**, Heidemann E, Langer C, Kanz L, Meisner C, Einsele H (2014): Autologous followed by allogeneic versus tandem-autologous stem cell transplant in newly diagnosed FISH-del13q myeloma. *Blood* 2014;124: abstr #43
100. Niederwieser D, Al-Ali HK, Krahl R, Kahl C, Wolf HH, Kreibich U, Vucinic V, Haehling D, Hegenbart U, Kraemer A, Hirt C, Peter N, Opitz B, Florschütz A, Reifenrath K, Schulze A, Zojer N, Scholl S, Jakob C, Junghanss C, Pönisch W, Heyn S, Sayer HG, Hochhaus A, Heinicke T, Fischer T, **Maschmeyer G**, Dreger P (2014): Higher leukemia free survival after post-induction hematopoietic cell transplantation compared to consolidation therapy in patients >60 years with acute myelogenous leukemia (AML): Report from the AML 2004 East German Study Group (OSHO). *Blood* 2014;124: abstr #280

101. Duehrsen U, Hüttmann A, Müller S, Hertenstein B, Kotzerke J, Mesters R, Franzius C, Kroschinsky F, Weckesser M, Franzke A, Bengel F, Dürig J, Matschke J, Pöppel T, Rekowski J, Ose C, Brinkmann M, LaRosée P, Freesmeyer M, Hertel A, Hoeffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Fricke E, Griesshammer M, Giagoundis A, Raghavachar A, **Maschmeyer G**, Brink I, Brecht A, Haberkorn U, Gaska T, Klapper W, Hoelzer D, Jöckel KH, Scherag A, Bockisch A (2014): Positron emission tomography (PET) guided therapy of aggressive lymphomas – a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial). *Blood* 2014;124: abstr #391
102. Borchmann P, Haverkamp H, Lohri A, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Engel N, Keller U, **Maschmeyer G**, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A (2014): Addition of rituximab to BEACOPPescalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: second planned interim analysis of the HD18 study. *Blood* 2014;124: abstr #500
103. Rummel MJ, Viardot A, Greil R, Hertenstein B, Lerchenmüller C, Ganser A, Reeb M, Kaiser U, Balsler C, **Maschmeyer G**, Dürk H, Schliesser G, Gaska T, Dürig J, Matzdorff AC, Weide R, Hinke A, Blau W, Burchardt A, Kauff F, Barth J, Brugger W (2014): Bendamustine plus rituximab followed by rituximab maintenance for patients with untreated advanced follicular lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial). *Blood* 2014;124: abstr #3052
104. Kahl C, Krahl R, Al-Ali HK, Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, **Maschmeyer G**, Hähling D, Junghanss C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D (2014): Long term follow up of the AML97-study for patients with AML older than 60 ears: a study of the East German Hematology and Oncology Study Group (OSHO). *Blood* 2014;124: abstr #3664
105. Heinicke T, Krahl R, Kahl C, Scholl S, Wolf HH, Hähling D, Hegenbart U, Peter N, Schulze A, Florschütz A, Reifenrath K, Zojer N, Jakob C, Junghanss C, Sayer HG, **Maschmeyer G**, Hochhaus A, Fischer T, Niederwieser D, Al-Ali HK (2014): Prognostic factors for overall survival in relapsed acute myeloid leukemia. *Blood* 2014;124: abstr #3666
106. Rummel MJ, **Maschmeyer G**, Ganser A, Heider A, von Grünhagen U, Losem C, Heil G, Welslau M, Balsler C, Kaiser U, Weidmann E, Dürk H, Böck HP, Stauch MB, Barth J, Blau W, Burchardt A, Kauff F, Hinke A, Brugger W (2014): Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL) – 7 year updated results from the StiL NHL1 study. *Blood* 2014;124: abstr #4407
107. Eichhorst B, Bahlo J, Fink AM, Pfreundschuh M, Hebart H, **Maschmeyer G**, Jentsch-Ulrich K, Dörfel S, Westermann A, Zey A, Fischer K, Wendtner CM, Noesslinger T, Ghia P, Bosch F, Kater AP, Kreuzer KA, Döhner H, Stilgenbauer S, Boettcher S, Hallek M (2014): Good tolerance of lenalidomide maintenance therapy in patients with high risk profile chronic lymphocytic leukemia (CLL) after frontline chemoimmunotherapy: preliminary safety overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). *Blood* 2014;124: abstr #4699
108. **Maschmeyer G** for the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) (2015): Pneumonia and lung infiltrates in leukemia and stem cell transplant patients: risk-adapted antimicrobial intervention in patients with hematological malignancies. *Ann Hematol* 2015; 94 (Suppl1): S65-66
109. Sinn M, Liersch T, Gellert K, Messmann H, Bechstein WO, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, **Maschmeyer G**, Pelzer U, Stieler J,

Striefeler JK, Ghadimi BM, Bahra M, Oettle H, Dörken B, Riess H (2015): CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study. *J Clin Oncol* 33, 2015 (suppl; abstr 4007)

91. **Jakob C, Peinert S, Breywisch F, Günther B, Dittberner K, Boger L, Rothmann F, Maschmeyer G** (2015): Low-dose cytarabine after failure of 5-azacitidine as palliative treatment for elderly patients with AML or high-risk MDS ineligible for intensive chemotherapy. 20th Congress of the European Hematology Association (EHA), Wien, 11.-14.6.2015, Abstract E967
92. Heinevetter B, Schenk T, Brunkhorst FM, **Maschmeyer G, Rothmann F**, Weber T, Müller M, Panse J, Janka G, Lehmsberg K, Hochhaus A, La Rosée P (2015): Hemophagocytic Lymphohistiocytosis (HLH) in adults: results of the German HLH registry. *Oncol Res Treat* 38(suppl 5):259
93. Rummel M, **Maschmeyer G**, Ganser A, Heider A, von Grünhagen U, Losem C, Heil G, Welslau M, Balsler C, Kaiser U, Weidmann E, Durk H, Balló H, Stauch M, Barth J, Blau W, Burchardt A, Kauff F, Brugger W (2015): Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas or mantle cell lymphomas (MCL) - 7-year updated results from the StiL NHL1 study. *Oncol Treat Res* 38(suppl 5):118
94. **Jakob C**, Kiewe P, Pohlkamp C, Oldenkott B, Kingreen D, Hopfer O, Jehn C, Linde H, Lüder F, Jahnke K, Göner M, Josting A, Sallmann D, **Rothmann F, Maschmeyer G**, Derwahl KM (2015): A retrospective multicenter analysis of clinical care and outcome in 178 patients with newly diagnosed symptomatic multiple myeloma in Berlin and the area of Brandenburg, between 2008 and 2011. *Cancer Res Treat* 38(suppl 5): 237
95. Niederwieser D, Hoffmann VS, Krug U, Krahl R, Sauerland C, Spiekermann K, Bohlander SK, Hegenbart U, Poenisch W, Vucinic V, Cross M, Jaekel N, Pfirrmann M, Schulze A, Kraemer A, **Maschmeyer G**, Junghanss C, Scholl S, **Jakob C**, Heinicke T, Haehling D, Peter N, Kreibich U, Busemann C, Al-Ali HK, Elmaagacli AH, Opitz B, Wolf HH, Hiddemann W, Berdel WE, Buechner T (2015): Higher incidence of secondary AML and adverse molecular markers, together with lower CR and higher AML related death rates in elderly compared to younger patients: results from 2435 patients included in the two German AML Intergroup studies. 57th ASH Annual Meeting, Orlando (FL), December 5-8, 2015, abstract #2517
96. Al-Ali HK, Jaekel N, Hubert K, Krahl R, Haenel M, **Maschmeyer G**, Herbst R, **Jakob C**, Schultze S, Wang SY, Brosteanu O, Niederwieser D (2015): Response-adapted sequential azacitidine and induction chemotherapy in patients > 60 years old with newly diagnosed AML eligible for chemotherapy (RAS-AZIC): first data of the interim analysis of the DRKS00004519 study of the East German Study Group (OSHO). 57th ASH Annual Meeting, Orlando (FL), December 5-8, 2015, abstract #1346
97. **Jakob C, Günther B, Dittberner K, Boger L, Bleienheuft P, Breywisch F, Rothmann F, Peinert S, Maschmeyer G** (2015): Second-line low-dose cytarabine after first-line treatment with 5-azacitidine in elderly patients with AML or high-risk MDS ineligible for intensive chemotherapy. A retrospective single center analysis. 57th ASH Annual Meeting, Orlando (FL), December 5-8, 2015, abstract #3780
98. Niederwieser N, Al-Ali HK, Krahl R, Kahl C, Wolf HH, Kreibich U, Vucinic V, Hegenbart U, Hirt C, Peter N, Opitz B, Florschütz A, Schulze A, Scholl S, **Jakob C**, Junghanss C, Sayer H, Hochhaus A, Fischer T, **Maschmeyer G**, for the East German Study Group (OSHO) (2016): Hematopoietic stem cell transplantation (HSCT) compared to consolidation chemotherapy (CT) to increase leukemia free survival (LFS) in acute myelogenous leukemia (AML) patients between 60 and 75 years irrespective of genetic

risk: Report from the AML 2004 of the East German Study Group (OSHO). J Clin Oncol 34, 2016 (suppl; abstr e18501)

99. Dietz A, Wichmann G, Flentje M, Hagen R, Koelbl O, Schreiber F, Schilling V, **Maschmeyer G**, Schroeder U, Sittel C, Lenarz T, Klussmann JP, Guntinas-Lichius O, Rudack C, Foerg T, Westhofen M, Welkoborsky HJ, Esser D, Held S, Keilholz U (2016): Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy (IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer (LHSCC). J Clin Oncol 34, 2016 (suppl; abstr 6025)
100. **Maschmeyer G** (2016): HPV – Impact and therapeutic implications in head and neck tumors. Oncol Res Treat 2016;39(suppl 3):248 (abstr V825)
101. Niederwieser D, Al-Ali HK, Krahl R, Kahl C, Wolf HH, Kreibich U, Vucinic V, Hähling D, Hegenbart U, Krämer A, Hirt C, Peter N, Opitz B, Florschütz A, Reifenrath K, Schulze A, Zojer N, Scholl S, **Jakob C**, Junghanss C, Pönisch W, Heyn S, Sayer HG, Hochhaus A, Heinicke T, Fischer T, Dreger P, **Maschmeyer G** (2016): Hematopoietic stem cell transplantation (HSCT) as compared to consolidation chemotherapy (CT) increases leukemia free survival in patients between 60 and 75 years with acute myelogenous leukemia (AML) irrespective of the genetic risk: Report from the AML 2004 of the East German Study Group (OSHO). Oncol Res Treat 2016;39(suppl 3):248 (abstr V29)
102. Jäkel N, Hubert K, Krahl R, Hänel M, **Maschmeyer G**, Herbst R, **Jacob C**, Schulze S, Wang SY, Cross M, Brosteanu O, Niederwieser D, Al-Ali HK (2016): Response-adapted sequential Azacitidine and induction chemotherapy in patients > 60 years with newly diagnosed AML eligible for chemotherapy: Interim analysis of the DRKS00004519 study (RAS-AZIC). Oncol Res Treat 2016;39(suppl 3):248 (abstr V178)
103. Birndt S, Schenk T, Brunkhorst FM, **Maschmeyer G**, **Rothmann F**, Weber T, Müller M, Panse J, Schroers R, Braess J, Frickhofen N, Janka G, Lehmsberg K, Hochhaus A, Ernst T, La Rosée P (2016): Clinical and laboratory findings in adult patients with hemophagocytic lymphohistiocytosis: Update from the German aHLH registry. Oncol Res Treat 2016;39(suppl 3):248 (abstr V474)
104. Schreder M, Liebisch P, Hebart H, Holler E, Engelhardt M, Metzner B, Peest D, Aulitzky W, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Peschel C, Heß G, Hertenstein B, Wolf HH, Jung W, Frickhofen N, **Maschmeyer G**, Langer C, Meisner C, Kanz L, Einsele H, Knop S, Deutsche Studiengruppe Multiples Myelom (2016): Randomized comparison of pegylated IFN- α 2b versus IFN- α 2b maintenance following tandem autologous transplant in multiple myeloma. Oncol Res Treat 2016;39(suppl 3):248 (abstr V546)
105. Rüssel J, von Einem J, Keilholz U, Dietz A, Grünewald V, **Maschmeyer G**, Kasper S, Rupprecht M, Sasse B, Melillo G, Krauss J (2016): RAPTOR, the global phase II, III clinical development program of the PD-L1 inhibitor Durvalumab (MEDI4736) in 2nd-line recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) - A German update on the HAWK, EAGLE and CONDOR trials. Oncol Res Treat 2016;39(suppl 3):248 (abstr V572)
106. Duehrsen U, Müller SP, Rekowski J, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Franzke A, Bengel FM, La Rosée P, Freesmeyer M, Hoeffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Aruna Raghavachar A, **Maschmeyer G**, Brink I, Schroers R, Gaska T, Dang TA, Giagounidis A, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nüchel H, Südhoff T, Römer W, Brinkmann M, Ose C, Hoelzer D, Dürig J, Jöckel KH, Klapper W, Hüttmann A (2016): Positron emission tomography (PET) guided therapy of aggressive lymphomas – Interim PET-based outcome prediction and treatment changes in patients with B cell lymphomas participating in the PETAL trial. 58th ASH Annual Meeting, San

Diego (CA), December 3-6, 2016, abstract #1857

107. Niederwieser D, Hoffmann VS, Pfirmann M, Al-Ali HK, Schwind S, Vucinic V, Krahl R, Kahl C, Wolf HH, Kreibich U, Hähling D, Hegenbart U, Hirt C, Peter N, Florschuetz A, Reifenrath K, Schulze A, Zojer N, Scholl A, Junghanss C, Pönisch W, Heyn S, Sayer HG, Hochhaus A, Heinicke T, Fischer T, Krämer A, Dreger P, **Maschmeyer G**, Krug U, Sauerland MC, Heinecke A, Hehlmann R, Lengfelder E, Hiddemann W, Serve H, Müller-Tidow C, Berdel WE, Büchner T (2016): Comparison of treatment strategies in patients over 60 years with AML: Final analysis of a prospective randomized German AML Intergroup study. 58th ASH Annual Meeting, San Diego (CA), December 3-6, 2016, abstract #1066
108. Birndt S, Thomas Schenk T, Brunkhorst FM, **Maschmeyer G**, **Rothmann F**, Weber T, Müller M, Panse JP, Roland Schroers R, Braess J, Frickhofen N, Janka G, Lehmsberg K, Hochhaus A, Ernst T, La Rosée P (2016): Hemophagocytic lymphohistiocytosis in adults (aHLH): Results from the German HLH Registry. 58th ASH Annual Meeting, San Diego (CA), December 3-6, 2016, abstract #2523
109. Rummel MJ, **Maschmeyer G**, Ganser A, Heider A, von Gruenhagen U, Losem C, Heil G, Welslau M, Balsler C, Kaiser U, Weidmann E, Dürk HA, Ballo H, Stauch M, Blau W, Burchardt A, Barth J, Kauff F, Brugger W (2017): Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study. *J Clin Oncol* 35, 2017 (suppl; abstr 7501)
110. Jaekel N, Hubert K, Krahl R, Haenel M, **Maschmeyer G**, Herbst R, **Jakob C**, Schultze S, Wang SY, Cross M, Kahl C, Wass M, Sayer H, Brosteanu O, Niederwieser D, Al-Ali HK (2017): Response-Adapted Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy: Results of the DRKS00004519 Study of the East German Study Group. 22nd Congress of the European Hematology Association, Madrid, June 22-25, 2017, *Haematologica* 2017;102(s1): 214 (abstract P555)
111. Rummel MJ, **Maschmeyer G**, Ganser A, Heider A, von Gruenhagen U, Losem C, Heil G, Welslau M, Balsler C, Kaiser U, Weidmann E, Dürk HA, Ballo H, Stauch M, Blau W, Burchardt A, Barth J, Kauff F, Brugger W, Studiengruppe indolente Lymphome (StiL) (2017): 10-year updated results from the StiL NHL1 study bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas. *Oncol Res Treat* 2017;40(Suppl 3):73
112. **Maschmeyer G** (2017): Novel treatment options for nasopharyngeal carcinoma. *Oncol Res Treat* 2017;40(Suppl 3):4
113. Sandherr M, Rieger C, **Maschmeyer G** (2017): Outpatient management of infectious complications in patients with malignant disorders: new guideline of the working party for infections in hematology and oncology (AGIHO). *Oncol Res Treat* 2017;40(Suppl 3):2
114. Dührsen U, Hüttmann A, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes H.-G, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, **Maschmeyer G**, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Rekowski J, Bockisch A, PETAL Trial Investigators (2017): Positron-emission tomography-guided therapy of aggressive non-Hodgkin lymphomas - final results of the PETAL trial. *Oncol Res Treat* 2017;40(Suppl 3):202
115. Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, **Maschmeyer G**, **Rothmann F**, Weber T, Müller M, Panse J, Schroers R, Braess J, Frickhofen N, Janka G, Lehmsberg K, Lachmann G, Hochhaus A, Ernst T, La Rosée P (2017): Hemophagocytic

lymphohistiocytosis (HLH): A cytokine storm disorder mimicking sepsis and a diagnostic pitfall on intensive care units. *Oncol Res Treat* 2017;40(Suppl 3):201-2

116. 253. Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, **Maschmeyer G**, Schalk E, Vehreschild JJ, Vehreschild M (2017): Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Oncol Res Treat* 2017;40(Suppl 3):2
117. Jäkel N, Hubert K, Krahl R, Hänel M, **Maschmeyer G**, Herbst R, **Jakob C**, Schulze S, Wang SY, Cross M, Kahl C, Wass M, Sayer HG, Brosteanu O, Niederwieser D, Al-Ali HK (2017): Response-adapted sequential azacitidine and induction chemotherapy in patients > 60 years old with newly diagnosed AML eligible for chemotherapy. Results of the DRKS00004519 study of the East German Study Group. *Oncol Res Treat* 2017;40(Suppl 3):27-28
118. Löhnert AY, Mayer K, von Lilienfeld-Toal M, Neumann S, Christopeit M, Alakel N, Henze L, Krause SW, Sandherr M, Weißinger F, Penack O, Wolf HH, Durán Graeff L, Cornely OA, **Maschmeyer G**, Vehreschild J (2017): New guidelines for prophylaxis of bacterial and pneumocystis infections. *Oncol Res Treat* 2017;40(Suppl 3):2
119. **Maschmeyer G** (2017): New AGIHO guidelines for the empirical antimicrobial therapy of febrile neutropenic patients. *Oncol Res Treat* 2017;40(Suppl 3):1
120. Rummel MJ, Buske C, Hertenstein B, Lerchenmüller C, Koenigsmann M, Lange E, Reeb M, Kaiser U, Balsler C, Behringer D, Dürig J, Gaska T, **Maschmeyer G**, Schliesser G, Burchardt AC, Barth J, Kauff F, Hinke A, Greil R (2017): Four versus two years of rituximab maintenance (R-maintenance) following bendamustine plus rituximab (B-R): Initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study). 59th ASH Annual Meeting, Atlanta (GA), December 9-12, 2017, abstract #483
121. Jaekel N, Hubert K, Krahl R, Haenel M, **Maschmeyer G**, Herbst R, **Jakob C**, Schulze S, Wang SY, Cross M, Kahl C, Wass M, Sayer HG, Brosteanu O, Niederwieser D, Al-Ali HK (2017): Response-adapted sequential treatment with azacitidine and intensive chemotherapy in patients > 60 years old with newly diagnosed AML: Results of the RAS-Azic trial of the East German Study Group (OSHO). 59th ASH Annual Meeting, Atlanta (GA), December 9-12, 2017, abstract #1334
122. Niederwieser D, Löwenberg B, Berdel WE, Brand R, Chalandon Y, Junghans C, Hasenclever D, Haenel M, **Maschmeyer G**, Mende M, Mohty M, Ossenkoppele GT, Passweg J, Sayer H, Schetelig J, Schouten HC, Schwind S, Stelljes M, Vucinic V, Cornelissen J, OSHO, HOVON, SAKK (2018): Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study. *J Clin Oncol* 36, 2018 (suppl; abstr 7045)
123. **Maschmeyer G** (2018): Positron emission / computed tomography vs elective neck dissection in locally advanced head-and-neck squamous cell carcinomas. *Oncol Res Treat* 2018;41(suppl 4): 10 (V57)
124. Rummel M, Buske C, Hertenstein B, Lerchenmüller CA, Koenigsmann M, Lange E, Reeb M, Kaiser U, Balsler C, Behringer D, Dürig J, Gaska T, **Maschmeyer G**, Schliesser G, Burchardt A, Barth J, Kauff F, Hinke A, Greil R (2018): Four versus two years of Rituximab maintenance (R-maintenance) following Bendamustine plus Rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study). *Oncol Res Treat* 2018;41(suppl 4): 251 (V757)

125. Jaekel N, Hubert K, Hänel M, **Maschmeyer G**, Herbst R, Schulze S, Wang SY, Kahl C, Wass M, Sayer HG, Brosteanu O, Niederwieser D, Al-Ali HK (2018): Outcome at two years after a response-adapted approach with azacitidine and intensive chemotherapy in patients > 60 years with newly diagnosed AML treated within the DRKS00004519 trial of the East German Study Group (OSHO). 60th ASH Annual Meeting, San Diego (CA), December 1-4, 2018, abstract #83
126. Jäkel N, Schulze S, Siebolts U, Haak A, Cross M, Niederwieser D, Haenel M, **Maschmeyer G**, Wass M, Heukamp L, Menon R, Bertrand M, Wickenhauser C, Al-Ali HK (2019): Impact of somatic mutations on response in patients > 60 years old with newly diagnosed AML treated with response-adapted sequential azacitidine and induction chemotherapy: results of the DRKS00004519 trial (RAS-AZIC) of the East German Study Group (OSHO). *Oncol Res Treat* 42 (suppl 4): 176-177
127. Fuchs M, Görgen H, Kobe C, Kuhnert G, Hitz F, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Söckler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, **Maschmeyer G**, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A (2019): PET positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study. *Oncol Res Treat* 42 (suppl 4): 306
128. Jaspers S, Jäkel N, Bach E, Noack N, Hänel M, **Maschmeyer G**, Niederwieser D, Al-Ali HK, Cross M (2019): Short term culture of primary AML MNCs under growth factor starvation reveals functional heterogeneity of potential prognostic relevance. *Oncol Res Treat* 42 (suppl 4): 262
129. Schalk E, **Maschmeyer G** (2019): Fieber und Lungeninfiltrate in der Neutropenie. *Oncol Res Treat* 42 (suppl 4): 162
130. Niederwieser D, Krahl R, Kahl C, Wolf HH, Scholl S, Cross M, Hegenbart U, Peter N, Niederwieser C, Florschütz A, Reifenrath K, Zojer N, **Jakob C**, Junghanss C, Sayer HG, Schmidt V, Schwind S, **Maschmeyer G**, Fischer T, Hochhaus A, Al-Ali HK, Heinicke T (2019): Incidence, risk factors, treatment and long term outcome of refractory and first relapse AML patients in the OSHO studies. 61st ASH Annual Meeting, Orlando (FL), December 7-10, 2019, abstract #1358
131. Jaekel N, Schulze S, Siebolt U, Haak A, Pazaitis N, Cross M, Niederwieser D, Hänel M, **Maschmeyer G**, Wass M, Heukamp L, Menon R, Bertrand M, Wickenhauser C, Brosteanu O, Al-Ali HK (2019): Impact of somatic mutations on outcome in patients > 60 years old with newly diagnosed AML treated with response-adapted sequential azacitidine and induction chemotherapy within the DRKS00004519 trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO). 61st ASH Annual Meeting, Orlando (FL), December 7-10, 2019, abstract #1420
132. Bachmann F, Held S, Engelhardt M, Langer C, Wolleschak D, Fleissner J, Mügge LO, Duerk H, Schreder M, Schaefer-Eckart K, Blau IW, Gramatzki M, Liebisch P, Reichle A, Metzler I, Bassermann F, Metzner B, Röllig C, Hertenstein B, Dechow T, Jung W, Ostermann H, Hebart H, **Maschmeyer G**, Salvwender HJ, von Lilienfeld-Toal M, Eckardt KU, Straka C, Einsele H, Knop S (2019): Patterns of renal recovery and toxicity with novel agent-based induction triplets in newly diagnosed multiple myeloma – an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group. 61st ASH Annual Meeting, Orlando (FL), December 7-10, 2019, abstract #1840